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E X ECU TI V E S U M M A RY

7

Obstetrics) brought together international experts to review and
summarize current knowledge of FGR.

Fetal growth restriction (FGR) is defined as the failure of the fetus

This summary is directed at multiple stakeholders, including

to meet its growth potential due to a pathological factor, most com-

healthcare providers, healthcare delivery organizations and pro-

monly placental dysfunction. Worldwide, FGR is a leading cause of

viders, FIGO member societies, and professional organizations.

stillbirth, neonatal mortality, and short- and long-term morbidity.

Recognizing the variation in the resources and expertise available

Ongoing advances in clinical care, especially in definitions, diagno-

for the management of FGR in different countries or regions, this

sis, and management of FGR, require efforts to effectively trans-

article attempts to take into consideration the unique aspects of

late these changes to the wide range of obstetric care providers.

antenatal care in low-resource settings (labelled “LRS” in the recom-

This article highlights agreements based on current research in the

mendations). This was achieved by collaboration with authors and

diagnosis and management of FGR, and the areas that need more

FIGO member societies from low-resource settings such as India,

research to provide further clarification of recommendations.

Sub-Saharan Africa, the Middle East, and Latin America.

The purpose of this article is to provide a comprehensive sum-

Aspects of FGR addressed in this article include prediction,

mary of available evidence along with practical recommendations

diagnosis, investigation, management, and postpartum counsel-

concerning the care of pregnancies at risk of or complicated by FGR,

ling. The main recommendations are given below and are sum-

with the overall goal to decrease the risk of stillbirth and neonatal

marized in Table 1 (section 8) and in the management algorithms

mortality and morbidity associated with this condition. To achieve

for high-resource settings (Figure 1a) and low-resource settings

these goals, FIGO (the International Federation of Gynecology and

(Figure 1b) (section 4).

Definitions
Quality of
evidence

Strength of
recommendation

1. Small for gestational age (SGA) is defined as an estimated fetal weight or birth weight below the 10th
percentile for gestational age.

⊕⊕⊕⊕

Strong

2. The definition of fetal growth restriction (FGR) should be based on a combination of measures of fetal
size percentile and Doppler abnormalities. We support the consensus-based definitions for early and late
fetal growth restriction by Gordijn et al.1 as described in Box 1 (section 4.2.1).
LRS In low-resource settings, FGR may be defined in the same way as SGA (fetal weight or birth weight
below the 10th percentile for gestational age).

⊕⊕

○○

Strong

Quality of
evidence

Strength of
recommendation

Recommendation

Prediction and prevention of fetal growth restriction (FGR)
Recommendation

○

Strong

○

Strong

○

Strong

○

Strong

○

Strong

○

Strong

1. Women should undergo risk stratification for FGR (and other placenta-mediated complications) at the
time of the first trimester antenatal visit using history-based (medical and obstetric) risk factors.

⊕⊕⊕

2. There is no evidence to support the routine use of biochemical markers for the prediction of FGR.
However, when such information is available as part of the prenatal genetic screening for trisomy 21,
it may be reasonable to use this information for the purpose of risk stratification for FGR (and other
placenta-mediated complications).

⊕⊕⊕

3. Ultrasound-based markers and multiparameter algorithms have only a moderate predictive accuracy for
FGR, and therefore currently cannot be recommended for universal screening.

⊕⊕⊕

4. Women at high risk for FGR should undergo close surveillance of fetal growth starting at 24–28 weeks.
LRS In low-resource settings, the frequency and type of monitoring may be limited by the availability
of obstetric ultrasound.

⊕⊕⊕

5. Women should be advised that smoking cessation and elimination of alcohol and illicit drugs can decrease
the risk of FGR.

⊕⊕⊕

6. Women should be advised on the association of insufficient gestational weight gain with FGR and be
informed regarding their target weight gain range.

⊕⊕⊕

7. There are insufficient data to recommend routine treatment with aspirin in all women at high risk of FGR.
Treatment with aspirin at a dose of 100–150 mg starting at 12–16 weeks may be considered in selected
cases such as women who are at high risk of pre-eclampsia or those with a history of placenta-mediated
FGR.

⊕⊕

8. Low-molecular-weight heparin is not recommended for the prevention of FGR in women at high risk of
FGR and its use should be limited to research settings.

⊕⊕⊕

○○
○

Weak

Strong

8
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Detection of fetal growth restriction (FGR)
Recommendation

Quality of
evidence

Strength of
recommendation

1. Symphysis–fundal height is a simple and inexpensive tool that can be used as the primary screening
strategy for FGR in low-risk pregnancies in both low- and high-resource settings.

⊕⊕⊕

○

Strong

2. There is no evidence to support routine third-trimester ultrasound for the detection of FGR, as this practice
has not been shown to be associated with improved perinatal outcomes.

⊕⊕⊕⊕

Strong

3. The choice of the equation used for sonographic fetal weight estimation may be based on validation within
the local population. If this information is not available, we recommend that the following equation of
Hadlock (based on head circumference [HC], abdominal circumference [AC], and femur length [FL]) should
be used2: Log10 weight =1.326 – 0.00326*AC*FL + 0.0107*HC + 0.0438*AC + 0.158*FL

⊕⊕⊕

○

Strong

4. Growth standards that are based on sonographic fetal weight estimation should be preferred over growth
references and over charts that are based on birth weight.

⊕⊕⊕

○

Strong

5. We support the recommendation of the FIGO Safe Motherhood and Newborn Health Committee that local
or regional growth charts should be preferred over universal charts.3 Alternatively, universal standards
may be used with locally adjusted thresholds to avoid under- or overdetection of FGR.

⊕⊕⊕

○

Strong

6. The decision regarding which growth chart to use may be further guided by comparing the performance of
the various charts in the population of interest, using local data sets.

⊕⊕

7. Based on the available evidence it seems reasonable to use twin-specific charts for the assessment of fetal
growth in twin gestations, as this has the potential to avoid overdiagnosis of FGR in this population.
8. In twin gestations, the diagnosis of FGR should also take into consideration intertwin size discordance,
especially in the case of monochorionic placentation.

○○

Weak

⊕⊕

○○

Weak

⊕⊕⊕⊕

Strong

Investigation of fetal growth restriction (FGR)
Quality of
evidence

Strength of
recommendation

1. Women with suspected FGR should undergo systematic assessment that includes the following: (1) detailed
history; (2) detailed sonographic assessment for structural anomalies, soft markers, and sonographic signs
related to fetal infection; (3) Doppler studies that include at least the umbilical artery and, when available,
also the uterine and middle cerebral arteries; and (4) maternal screening for relevant congenital infections,
which should be focused on cytomegalovirus and toxoplasmosis, but may also include rubella, herpes,
syphilis, malaria, and Zika virus in cases at high risk.
LRS The extent of investigation may be limited by available resources. Assessment should include
screening for infections such as malaria and Zika virus in endemic areas.

⊕⊕⊕⊕

Strong

2. Confirmation of gestational age should be the first step when FGR is suspected. With the exception of
pregnancies achieved by assisted reproductive technology, first-trimester crown–rump length is the most
accurate method to date pregnancy when in the range of 7–60 mm. If more than one scan is performed in
the first trimester, the earliest scan with a crown–rump length of at least 10 mm should be used.
LRS In low-resource settings, dating may need to be based on menstrual history or symphysis–fundal height.

⊕⊕⊕⊕

Strong

3. Amniocentesis for karyotype (as well as microarray and polymerase chain reaction for infectious agents when
available) should be offered to women with suspected FGR, especially in cases with early-onset severe (estimated
fetal weight <3rd percentile) FGR, in the presence of sonographic findings associated with genetic or infectious
etiologies, no obvious signs of placental dysfunction, and when the findings are likely to affect management.
LRS The availability of genetic testing may be limited by available resources.

⊕⊕⊕

○

Strong

Recommendation

Management of fetal growth restriction (FGR)
Recommendation

Quality of
evidence

Strength of
recommendation

○○

Strong

○

Strong

1. Fetal movement counting is a simple and inexpensive tool that may decrease the risk of stillbirth in
pregnancies with FGR in both high- and low-resource settings.

⊕⊕

2. Surveillance in pregnancies with FGR should follow a uniform protocol that is based on a combination
of biophysical (cardiotocogram/nonstress test [CTG/NST], computerized fetal heart rate monitoring
[cCTG], biophysical profile) and cardiovascular (umbilical artery and middle cerebral artery, with or
without ductus venosus Doppler) parameters along with predetermined thresholds for delivery.
LRS In low-resource settings, the combination of CTG/NST and umbilical artery Doppler provides
sufficient accuracy for the detection of fetal deterioration.

⊕⊕⊕

|
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Management of fetal growth restriction (FGR) Cont.
Recommendation

Quality of
evidence

Strength of
recommendation

3. In late-onset FGR, middle cerebral artery Doppler and the cerebroplacental ratio can provide additional
information on fetal deterioration and should be included as part of the Doppler assessment.
LRS In cases where middle cerebral artery Doppler is not available, twice weekly CTG/NST monitoring
in cases of late FGR with normal umbilical artery Doppler provides a similar safety net as middle cerebral
artery Doppler.

⊕⊕

○○

Strong

4. Absolute indications for delivery irrespective of gestational age include biophysical profile or CTG/NST
abnormalities (reduced variability and/or repetitive late decelerations), or severe pre-eclampsia with
uncontrolled hypertension, HELLP syndrome, or other types of end organ damage.

⊕⊕⊕⊕

Strong

5. In cases of isolated mild SGA (estimated fetal weight at 3rd–9th percentile) with no additional
abnormalities (i.e. normal fluid and Doppler studies), delivery may be deferred until 37–39 weeks. Until
then, monitoring should include umbilical artery and middle cerebral artery Doppler at an interval of
1–2 weeks. For mild SGA at term (≥37 weeks), monitoring with CTG/NST and/or biophysical profile
1–2 times per week may be considered in addition to Doppler studies.

⊕⊕⊕

○

Strong

6. In cases of isolated severe SGA (estimated fetal weight <3rd percentile) with no additional abnormalities,
delivery may be deferred until 36–38 weeks. Until then, monitoring should include umbilical artery and
middle cerebral artery Doppler 1–2 times per week. For severe SGA at term (≥37 weeks) monitoring
with CTG/NST and/or biophysical profile 1–2 times per week may be considered in addition to Doppler
studies.

⊕⊕⊕

○

Strong

7. In cases of FGR with early Doppler changes or mild associated abnormalities (oligohydramnios, suboptimal
interval growth, pre-eclampsia), delivery may be deferred until 34–37 weeks. Until then, monitoring
should include CTG/NST and/or biophysical profile twice per week and Doppler 1–2 times per week.

⊕⊕

○○

Strong

8. In cases of FGR with umbilical artery absent end-diastolic velocity (AEDV), delivery may be deferred until
32 weeks. Until then, inpatient monitoring is recommended with CTG/NST and/or biophysical profile
1–2 times per day and Doppler 3 times per week.

⊕⊕

○○

Strong

9. In cases of FGR with umbilical artery reversed end-diastolic velocity (REDV), delivery may be deferred
until 30 weeks. Until then, inpatient monitoring is recommended with CTG/NST and/or biophysical
profile twice per day and daily Doppler.

⊕⊕

○○

Strong

10. In cases of FGR with abnormal ductus venosus Doppler, delivery may be recommended as early as
26–30 weeks. Timing should be individualized based on local neonatal outcomes. Intensive inpatient
monitoring is recommended with CTG/NST and/or biophysical profile twice per day and daily Doppler. Before
26 weeks, careful and shared decision making with the parents and neonatology team is recommended.

⊕⊕

○○

Weak

11. FGR alone is not an indication for cesarean section. Primary cesarean section may be considered in cases
of early-onset FGR with umbilical artery AEDV/REDV or ductus venosus Doppler changes, abnormal
CTG/NST or biophysical profile, maternal indications such as severe pre-eclampsia, or contraindications
for vaginal birth. In the absence of these conditions, induction of labor should be preferred.

⊕

○○○

Strong

12. Delivery of FGR fetuses should ideally take place at centers with the appropriate level of neonatal care
for the gestational age and with the ability to perform urgent cesarean section if needed. During labor,
continuous fetal heart rate monitoring is recommended.

⊕⊕⊕⊕

Strong

13. The placenta should be sent for histopathological examination where available as it may provide useful
information for counselling regarding future pregnancies.

⊕⊕

○○

Strong

14. The administration of antenatal corticosteroids in FGR pregnancies should follow the same protocol
used in pregnancies not affected by FGR. Close fetal monitoring should be considered when antenatal
corticosteroids are administered in fetuses with severe FGR with late Doppler changes.

⊕⊕⊕

○

Strong

15. The administration of magnesium sulfate for neuroprotection in preterm FGR pregnancies should follow
the same protocol used in pregnancies not affected by FGR.

⊕⊕

○○

Strong

16. There are currently no proven treatments for FGR.

⊕⊕⊕

○

Strong

9
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Postpartum assessment and counselling for future pregnancies in women with a history of fetal growth restriction (FGR)
Recommendation

Quality of
evidence

○○

Strong

○

Strong

○○

Strong

⊕⊕⊕

○

Strong

○
⊕⊕○○

Strong

○

Strong

1. Growth restricted infants are at an increased risk of short- and long-term morbidity and should be
followed postnatally more closely than normally grown infants.

⊕⊕

2. Women with a history of placenta-mediated pregnancy complications including FGR are at an increased
risk of future cardiovascular morbidity and should be advised regarding preventive strategies as
reviewed in detail in the FIGO postpregnancy initiative on long-term maternal implications of pregnancy
complications and follow-up considerations.4

⊕⊕⊕

3. Women with a history of FGR should be counselled regarding the risk of recurrence based on timing of
onset, severity of FGR, and placental histopathological findings.

⊕⊕

4. Women with a history of FGR should not be routinely screened for antiphospholipid antibodies in the
absence of a history of thromboembolism or pregnancy loss.
5. There is no role for screening for hereditary thrombophilias in women with a history of FGR.

⊕⊕⊕

6. The following preventive interventions are recommended in women with a history of placenta-mediated
FGR and those at risk of pre-eclampsia: smoking cessation, aspirin at a dose of 100–150 mg taken in the
evening starting at 12–16 weeks.

Strength of
recommendation

7. Low-molecular-weight heparin is not recommended for the prevention of FGR in women with a history of
placenta-mediated FGR.

⊕⊕⊕

8. In women with antiphospholipid syndrome and a history of placenta-mediated FGR, low-molecularweight heparin may be considered in selected cases, such as in women who have experienced recurrent
complications despite aspirin treatment (aspirin failure).

⊕⊕

9. Women with a history of FGR should undergo close surveillance of fetal growth starting at 24–28 weeks.

⊕⊕⊕

○○
○

Strong

Weak

Strong

|
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practitioners, midwives, nurses, advance practice clinicians, radiologists, sonographers, pediatricians, and neonatologists).

This article is directed at multiple stakeholders with the intention

Healthcare delivery organizations and providers: governments,

of bringing attention to the assessment of fetal growth, with a par-

federal and state legislators, healthcare management organizations,

ticular focus on the screening, diagnosis, and management of FGR,

health insurance organizations, international development agencies,

which is a leading cause of stillbirth and neonatal mortality and mor-

and nongovernmental organizations.

bidity. This article proposes to standardize and provide guidance for
the screening, prevention, diagnosis, and management of FGR.

Professional organizations: international, regional, and national
professional organizations of obstetricians and gynecologists,

The intended target audience includes:

obstetric ultrasound, family practitioners, pediatricians, neonatolo-

Healthcare providers: all those qualified to care for pregnant

gists, and worldwide national organizations dedicated to the care of

women (obstetricians, maternal-fetal medicine specialists, general

pregnant women and their offspring.
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3 | A S S E S S M E NT O F Q UA LIT Y O F
E V I D E N C E A N D G R A D I N G O F S TR E N G TH
O F R ECO M M E N DATI O N S

Melamed et al.

represent a benefit that outweighs the risks and burdens, and therefore may be strongly recommended.
The overall quality of evidence was assessed for each of the recommendations and expressed using four levels of quality: very low,

In assessing the quality of evidence and grading of strength of rec-

low, moderate, and high (Table S2).7 Considerations for quality of

ommendations, the article follows the terminology proposed by

evidence include primarily the study design and methodology. As

the Grading of Recommendations, Assessment, Development and

such, evidence based on randomized controlled trials is considered

Evaluation (GRADE) Working Group.5 This system uses consistent

high-quality evidence, observational studies provide moderate or

language and graphical descriptions for the strength and quality of

low quality of evidence, and all others are very low. However, other

the recommendations and the evidence on which they are based.

parameters must be considered while assessing the level of evidence:

Recommendations are classified as strong or conditional (weak)

risk of bias, study limitations, consistency of results, precision, pub-

(Table S1).6 The strength of recommendation is dependent not only

lication bias, indirectness of evidence, and scarcity of evidence. For

on the quality of evidence, but also on factors such as risk–bene-

the quality of evidence, cross-filled circles are used: ⊕○○○ denotes

fit, cost, resource allocation, values, and preferences. Thus, some
recommendations may be based on low-quality evidence but still

very low-quality evidence; ⊕⊕○○ low quality; ⊕⊕⊕○ moderate

quality; and ⊕⊕⊕⊕ high-quality evidence.
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4 | FE TA L G ROW TH R E S TR I C TI O N :
BAC KG RO U N D, D E FI N ITI O N , E TI O LO G Y,
AND RISKS
4.1 | Background

13

It should be noted that there is inconsistency in the literature
regarding the terminology described above, where some use the
term FGR to describe a fetus with an estimated weight below the
10th percentile for gestational age and the term SGA to describe
an infant with birth weight below the 10th percentile for gestational age. However, for the purpose of this article, the term SGA

FGR is a common pregnancy complication that worldwide is a lead-

is used to indicate an EFW or birth weight below the 10th per-

ing cause of stillbirth, neonatal mortality, and short- and long-term

centile for gestational age, and the term FGR to refer to a small

neonatal morbidity.8-15 The definition, diagnosis, and optimal man-

fetus that has failed to achieve its growth potential because of a

agement of FGR have generated controversy as clinicians strive for

pathologic process.

more harmonized care.
The purpose of this article is to provide a summary of the available evidence and provide recommendations regarding the early
prediction and prevention, diagnosis, investigation, monitoring,

4.2.1 | Consensus-based definition of placentarelated FGR

and timing of delivery of pregnancies complicated by FGR, with
the overall goal to decrease the risk of stillbirth and neonatal mor-

The major member societies of FIGO follow a definition using the

tality and morbidity associated with this pregnancy complication.

10th percentile as a means of diagnosing an SGA fetus, which then

Given the variation in resources and expertise available for the

leads to further testing, assessment, and follow-up. There are pro-

assessment and monitoring of pregnancies complicated by FGR

posals to address the limitations of this definition, but their validity

in different countries or regions, we have included, in addition to

regarding reduction in adverse outcomes needs to be tested. For

the standard of care or “best” recommendations, specific recom-

example, in an attempt to overcome some of the limitations de-

mendations for low-resource settings, which are marked as LRS

scribed above, a consensus-based definition for placenta-mediated

in the recommendation tables. Management algorithms for women

FGR has been proposed via a Delphi procedure.1 To decrease the

in high-resource and low-resource settings are summarized in

likelihood of false-positive and false-negative diagnosis of FGR,

Figure 1a and 1b, respectively.

the consensus definition was based on a combination of measures
of fetal size (fetal weight estimation and abdominal circumference)

4.2 | Terminology and definitions

and abnormal Doppler findings in the umbilical, uterine, and middle cerebral arteries, as described in Box 1. The implementation of
this definition is limited by the lack of a recommendation on which

FGR is defined as the failure of the fetus to meet its growth potential

growth chart should be used to define the 10th and 3rd percentiles

due to a pathological factor, most commonly placental dysfunction.

for EFW and fetal abdominal circumference. In addition, further

Clinically, this is reflected by a drop in fetal size percentiles over the

research is needed to correlate this definition with adverse peri-

course of gestation. However, fetal growth potential is difficult to

natal outcomes.

determine, and serial assessments of fetal size to detect a drop in
fetal weight percentile are usually not available. Instead, care providers most commonly have only a “snapshot” of fetal weight estima-

4.2.2 | Early- versus late-onset FGR

tion at a given point in time. Therefore, in clinical practice, small for
gestational age (SGA), defined as estimated fetal weight (EFW) or

It has been suggested that FGR should be broadly classified, based

abdominal circumference below a certain threshold such as the 10th

on gestational age at the time of diagnosis, into early-onset FGR

or 3rd percentile, is most commonly used to suspect FGR.

(<32 weeks) and late-onset FGR (≥32 weeks). The rationale under-

The use of SGA as a proxy for FGR has several limitations that

lying this classification is based on differences between these two

need to be recognized. First, most SGA fetuses are constitution-

phenotypes of FGR in severity, natural history, Doppler findings,

ally healthy small fetuses, whose smallness is merely the result of

association with hypertensive complications, placental findings, and

their predetermined growth potential (i.e. false-positive diagnosis of

management.16-18

FGR). Second, some growth-restricted fetuses, depending on their

Early-onset FGR has a prevalence of 0.5%–1%, is usually more

original growth potential and timing of insult, may remain above the

severe, and is more likely to be associated with abnormal umbili-

percentile threshold described above and may thus not be SGA (i.e.

cal artery Doppler than late-onset FGR. The underlying placental

false-negative diagnosis of FGR). Third, the use of SGA as a proxy

pathology is frequently similar to that observed in cases of early-onset

for FGR is limited by the accuracy of sonographic fetal weight esti-

pre-eclampsia (maternal vascular malperfusion), which explains the

mation, which has an estimation error of up to ±15%–20%. Finally,

strong association of early-onset FGR with pre-eclampsia. Therefore,

the diagnosis of SGA is highly dependent on the growth chart being

early-onset FGR is usually easier to detect, and the natural history

used, which can therefore have a considerable effect on the propor-

tends to follow a predictable sequence of Doppler changes in the

tion of fetuses or infants flagged as SGA in a given population.

umbilical artery and ductus venosus. The main challenge in cases of

14

|

Melamed et al.

F I G U R E 1 A Approach to screening, diagnosis, and management of fetal growth restriction in high-resource settings. Abbreviations: FGR,
fetal growth restriction; NST, nonstress test; PCR, polymerase chain reaction; SFH, symphysis–fundal height.

early-onset FGR is management (i.e. timing of delivery), by attempt-

that the diagnosis is commonly made during the late-preterm or

ing to determine the optimal balance between the opposing risks of

term periods, where the risks associated with delivery are rela-

stillbirth and prematurity.19

tively small. The diagnosis of late-onset FGR mainly relies on

Late-onset FGR is more common than early-onset FGR with

adaptive changes in the cerebral circulation (“redistribution” or

a prevalence of 5%–10%. In contrast to early-onset FGR, it is

“brain-sparing effect”), which is reflected by low resistance to

usually milder, is less likely to be associated with pre-eclampsia,

flow in the middle cerebral artery thereby generating a low cere-

and is usually associated with normal umbilical artery Doppler.

broplacental ratio, as described in section 8.1.7. Given that the

Therefore, the main challenge with regard to late-onset FGR is di-

umbilical artery and ductus venosus Doppler studies are usually

agnosis, while management (i.e. delivery) is relatively simple given

normal in cases of late-onset FGR, the natural history in these

|
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F I G U R E 1 B Approach to screening, diagnosis, and management of fetal growth restriction in low-resource settings. Abbreviations: FGR,
fetal growth restriction; NST, nonstress test; PCR, polymerase chain reaction; SFH, symphysis–fundal height.

Box 1 Consensus-based definitions for fetal growth restriction.
Early-onset FGR (<32 weeks)
• EFW or AC <3rd percentile
or
• UA with AREDV
or
• EFW or AC <10th percentile, combined with one or more of the
following:
a. UA PI >95th percentile
b. UtA PI >95th percentile

Late-onset FGR (≥32 weeks)
• EFW or AC <3rd percentile
or
• ≥2 of the following 3 criteria:
a. EFW or AC <10th percentile
b. EFW or AC crossing percentiles >2 quartiles on growth
percentiles
c. CPR <5th percentile or UA PI >95th percentile

Abbreviations: AC, fetal abdominal circumference; AREDV, absent or reversed end-diastolic velocity; CPR, cerebroplacental ratio;
EFW, estimated fetal weight; PI, pulsatility index; UA, umbilical artery; UtA, uterine artery. Adapted from Gordijn et al.1
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Box 2 Common etiologies of fetal growth
restriction.
Suboptimal uteroplacental perfusion of fetal nutrition
a. Maternal (preplacental) factors
• Hypoxemia (chronic lung disease, high altitude)
• Anemia
• Smoking, substance abuse (cocaine,
methamphetamines)
• Malabsorption, poor weight gain
• Environmental toxins: air pollution, heavy metals
(lead, mercury), perfluorooctanoic acid (PFOA)
b. Placental factors
• Maternal vascular malperfusion pathology (infarction,
fibrin deposition, chronic abruption)
• Fetal vascular malperfusion pathology
• Chronic placental inflammation (e.g. villitis of
unknown etiology)
• Confined placental mosaicism
c. Umbilical cord (postplacental) factors
• Increased coiling
• Increased cord length
• True cord knot
• Single umbilical artery
• Marginal or velamentous cord insertion
Fetal disorders
• Genetic disorders (chromosomal, microdeletions/
duplications, single site mutations, epigenetic
disorders)
• Structural anomalies (e.g. congenital heart disease,
gastroschisis)
• Congenital infections (cytomegalovirus,
toxoplasmosis, herpes, rubella, syphilis, Zika virus,
malaria)
• Teratogen exposure (drugs, toxins)

Box 3 Risks associated with fetal growth
restriction.
Antenatal
• Stillbirth
• Pre-eclampsia
• Placental abruption
• Preterm birth
Neonatal (short term)
• Neonatal mortality
• Neonatal morbidity (hypoglycemia, hyperbilirubinemia,
hypothermia, necrotizing enterocolitis, respiratory
morbidity, intraventricular hemorrhage)
Neonatal (long term)
• Neurodevelopmental disorders
• Metabolic syndrome (obesity, hypertension, diabetes,
cardiovascular disease)

preventing FGR. While the mechanisms by which maternal anemia
contributes to FGR are unclear, both impaired nutrient transport to
the fetus 27 and abnormal placental adaptation to low maternal hemoglobin 28 have been suggested as potential mechanisms.
Abnormal placentation is a common cause of FGR,
often diagnosed by ultrasound Doppler studies

30

29

which is

and typical histo-

pathological placental findings.31-33
Chromosomal abnormalities have been suggested to contribute to up to 5% of FGR cases; triploidy and trisomy 13 and 18 are
important considerations in early-onset FGR and the risk of many
aneuploidies is higher in the presence of structural fetal anomalies.34-36 In 1%–6% of cases of FGR with normal karyotype, submicroscopic (micro) duplications/deletions can be found using
chromosomal microarray analysis,35 even when FGR is an apparently

cases is less predictable and there is a risk of sudden decompen-

isolated finding.37 FGR is also more prevalent in fetuses with struc-

sation and stillbirth.16,19

tural malformations, and the risk increases when multiple anomalies
are present.38

4.3 | Etiology of fetal growth restriction

FGR is related to intrauterine infection in up to 5% of cases. 20,39
Viral agents such as rubella, cytomegalovirus, HIV, and Zika are
common causes of infection-related FGR.40-44 Protozoan infec-

FGR is often the result of one or more maternal, placental, or fetal

tions like toxoplasmosis and malaria are another important cause,

disorders that interfere with the normal mechanisms regulating fetal

especially in endemic areas.45,46 The main mechanism involved in

growth.

20,21

The most common etiologies of FGR are listed in Box 2. It is

the pathogenesis of FGR in these cases is a decline in cell popu-

important to note that there is often confusion in the literature between

lation. 20 Finally, maternal exposure to teratogens such as radia-

“etiologies” (or pathogenetic pathways) and “risk factors” for FGR. For

tion,47 illicit drugs,48,49 and alcohol50 is another important etiology

example, although maternal conditions such as chronic hypertension,

of FGR.

kidney disease, systemic lupus erythematosus, and long-standing diabetes are often listed as “maternal etiologies” for FGR, these conditions
should probably be viewed instead as maternal risk factors for abnormal

4.4 | Risks associated with fetal growth restriction

placentation that may result in placenta-mediated FGR.
Given that maternal nutrition and fetal growth are closely
related,

22,23

The main short- and long-term risks associated with FGR are listed

maternal undernutrition is an important cause of FGR

in Box 3. It is associated with both fetal and obstetric complica-

worldwide.24-26 The impact of maternal undernutrition on fetal growth

tions. The most devastating complication is stillbirth, 51-53 and there

depends on its timing and severity.

20

To date, maternal interventions

is a well-established inverse relationship between weight percentile

in dietary advice and modifications have lacked significant success in

and the risk of stillbirth, 54-57 which is more pronounced in the early
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preterm period than at term. 58 FGR is an important cause of iatro-

are independent predictors of neonatal complications. 68 Among

genic preterm birth, 59 as early delivery remains the main and per-

preterm infants, the co-presence of FGR further increases the risk

haps only strategy for the prevention of stillbirth in cases of severe

of certain prematurity-related complications such as respiratory

FGR.16,60 FGR is also an independent risk factor for spontaneous

morbidity, intraventricular hemorrhage, necrotizing enterocolitis,

preterm birth.61 Other obstetric complications associated with FGR

and metabolic disorders. 57 Among term infants, FGR increases

include pre-eclampsia and placental abruption, as the pathophysiol-

the risks of low cord artery pH, 69 low Apgar score, 69 and neo-

ogy of these conditions is often closely related.

29,30,62-66

natal complications such as hypoglycemia, hypothermia, and

Despite ongoing improvements in neonatal care, FGR is associated with increased neonatal mortality and short-term morbidity.
The risk of perinatal mortality in term FGR is reported to be fiveto 10-fold higher than in appropriately grown neonates.

57,61,67

The

severity of FGR, Doppler abnormalities, and associated prematurity

jaundice.70-72
Growth-restricted infants are also at risk of long-term complications including neurodevelopmental impairment
15,79-82

communicable diseases.

11,73-78

and non-

This is discussed in greater detail in

section 9.1 (Infant follow-up).

4.5 | Recommendations
FIGO recommends the following for the definition of fetal growth restriction (FGR)
Quality of
evidence

Strength of
recommendation

1. Small for gestational age (SGA) is defined as an estimated fetal weight or birth weight below the 10th
percentile for gestational age.

⊕⊕⊕⊕

Strong

2. The definition of FGR should be based on a combination of measures of fetal size percentile and Doppler
abnormalities. We support the consensus-based definitions for early and late fetal growth restriction by
Gordijn et al.1 as described in Box 1 (section 4.2.1).
LRS In low-resource settings, FGR may be defined in the same way as SGA (fetal weight or birth weight
below the 10th percentile for gestational age).

⊕⊕

○○

Strong

Recommendation
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5 | E A R LY PR E D I C TI O N A N D
PR E V E NTI O N O F FE TA L G ROW TH
R E S TR I C TI O N

5.1 | History-based risk factors
Several maternal factors influence fetal growth and the risk of FGR:
advanced maternal age, racial/ethnic origin (e.g. South Asian), con-

Early prediction of FGR is important as it can identify women at

sanguinity, low body mass index, nulliparity, use of recreational

high risk of FGR who may benefit from preventive interventions and

drugs and alcohol, assisted reproductive technology, and medi-

close monitoring during pregnancy. Box 4 lists the most common risk

cal disorders such as chronic hypertension, diabetes mellitus, and

factors for FGR. While the predictive value of individual risk factors

autoimmune conditions (Box 4).83-89 Cigarette smoking is a com-

is low, clinical prediction models that are based on combinations of

mon risk factor for FGR and reduces birth weight by an average of

the risk factors outlined below can considerably improve the predic-

200 g in a dose–response manner.90 In a cohort of 33 602 pregnan-

tion of FGR. One important limitation of most of the studies on early

cies, maternal characteristics predicted 37% of women who subse-

prediction of FGR is the lack of a gold standard for the antenatal or

quently delivered SGA neonates (birth weight <5th percentile) at a

postnatal diagnosis of FGR. As such, there is wide variation among

false-positive rate of 10%.83

studies regarding the outcomes being predicted, including either

Some risk factors for FGR are especially relevant in low-resource

SGA (birth weight below the 10th or 3rd percentile) or adverse peri-

countries. In a recent review from Africa, the main risk factors

natal outcomes that are associated with (but are not specific to) FGR.

reported were low maternal nutritional status, HIV infection,

As many SGA infants are constitutionally small and healthy, differ-

malaria, and hypertensive diseases. Based on these findings, the

entiating between healthy small fetuses and those that are small due

authors concluded that to a large extent FGR in Africa is preventable

to FGR is critically important. As a rule, the prediction of early-onset

through established interventions for malaria, HIV, and maternal

severe FGR is better than of late-onset FGR.

undernutrition.42 In addition, exposure during pregnancy and lactation to toxic environmental chemicals and heavy metals has become
a growing problem, especially in low-resource countries.91

Box 4 Risk factors for fetal growth restriction.
History-based risk factors
a. Maternal demographics
• Advanced age
• Underweight
• Living in high altitude
• Severe anemia, hemoglobinopathies
• Environmental factors (air pollution, heavy metals,
heat)
b. Medical conditions
• Chronic hypertension
• Chronic kidney disease
• Systemic lupus erythematosus
• Inflammatory bowel disease
• Antiphospholipid syndrome
• Pregestational diabetes (long standing)
c. Obstetric history
• Previous pregnancy affected by FGR or pre-eclampsia
Biochemical markers
• Low PlGF
• Low PAPP-A
• High AFP
Ultrasound-based markers
• Uterine artery: pulsatility index >95th percentile
• Uterine artery: bilateral notching
• Marginal or velamentous cord insertion
• Two-vessel cord (single umbilical artery)
• Abnormal placental morphologya
• Decreased fetal growth velocity

Abbreviations: FGR, fetal growth restriction; PlGF, placental growth factor; PAPP-A, pregnancy-associated plasma
protein-A; AFP, alpha-fetoprotein.
a

Refers to placental dimension (short-based thick placenta)

and texture (calcifications, echogenic cystic lesions).

5.2 | Biochemical markers
At this point there is no role for routine screening with serum biomarkers for FGR. However, when biochemical markers are available as part
of prenatal genetic screening for trisomy 21, it may be reasonable to
use this information for the purpose of risk stratification for FGR.
The placenta releases multiple factors into maternal circulation
from the early stages of pregnancy, and first-trimester serum levels
of some of these factors have been shown to be associated with
subsequent placenta-mediated complications.92,93 Low levels of
pregnancy-associated plasma protein-A (PAPP-A), a placental glycoprotein produced by the syncytiotrophoblast layer, have been
associated with adverse pregnancy outcomes including SGA. A
meta-analysis including 32 studies and 175 240 pregnancies found
that PAPP-A levels below the 5th percentile had a moderate association with birth weight below the 10th percentile (OR 2.08, positive predictive value of 18%), while the association was stronger
for PAPP-A levels below the 1st percentile (OR 3.4; positive predictive value of 28%).94 Thus, although women with low PAPP-A are
at increased risk for FGR, the majority of these women will have
a normal pregnancy outcome, especially as an isolated biomarker
in healthy women. However, a low PAPP-A level is often considered an indication for closer monitoring of fetal growth.95 Elevated
second-trimester maternal serum levels of alpha-fetoprotein are
thought to reflect abnormal placental permeability and are associated with increased risk of placenta-mediated complications including FGR and stillbirth.96,97 The combination of low PAPP-A in the
first trimester and high alpha-fetoprotein in the second trimester is
particularly predictive of severe FGR.98 Elevated human chorionic
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gonadotropin (hCG) levels greater than 2.5 MoM in the second tri-

two-dimensional (2D) placental ultrasound examination has been

mester, alone or combined with high alpha-fetoprotein levels, are

described, often in combination with other parameters

99

also associated with an increased risk of SGA.

30,113,114

Abnormal placental morphology is defined by placental dimensions,

Angiogenic factors play a key role in the regulation of placental

shape, texture, and cord insertion. Placental shape is considered

vascular development.100 Placental growth factor (PlGF) is a pro-

abnormal when the placental thickness is above 4 cm or greater than

angiogenic factor highly expressed in the syncytiotrophoblast and

50% of placental length. Placental texture is defined as normal when

the maternal endothelium. Impaired placentation is associated with

it is homogenous, and abnormal when the placenta is heterogeneous

reduced placental production of this protein. Low first-trimester

and contains multiple echogenic cystic lesions or has a jelly-like

PlGF levels have been shown to be associated with adverse preg-

appearance with turbulent uteroplacental flow.115,116 Placental cord

nancy outcome including pre-eclampsia and SGA.101-104 In a case–

insertion is defined as central (>2 cm from placental disc margin),

control study of 296 pregnancies with SGA and 609 controls, the

marginal (within 2 cm of margin), or velamentous (inserting into the

detection rate of low PlGF for SGA at a false-positive rate of 5%

surrounding membranes).114 In a cohort of 60 high-risk women with

and 10% was 15% and 21%, respectively. The combined use of PlGF

abnormal uterine artery Doppler, women with abnormal placental

and PAPP-A increased the detection rate to 19% and 27%, respec-

shape at 19–23 weeks had higher odds of FGR (OR 4.7) than women

tively.103 A multicenter screening study found that the detection

with normal placental shape.108 However, the use of 2D placental

rate of a combined screening by maternal factors, fetal biometry,

imaging has significant limitations, including difficulty in assessing

and serum PlGF and alpha-fetoprotein at 19–24 weeks for the deliv-

nonanterior placentas and a wide variability in the morphology of

ery of SGA infants below the 5th percentile at less than 32, 32–36,

normal placentas. Furthermore, there are no large-scale prospective

and greater than or equal to 37 weeks of gestation was 100%, 76%,

studies validating the use of this modality for prediction of FGR.114

96

Improvements in ultrasonographic imaging provide a tool for

and 38%, respectively, at a false-positive rate of 10%.

Findings are less consistent for soluble fms-like tyrosine kinase-1

estimating placental volume using three- and four-dimensional scan-

(sFlt-1), an antiangiogenic factor released from the placenta that results

ning techniques. Placental volume has been proposed as a marker

in maternal endothelial dysfunction characteristic of pre-eclampsia.105

for various obstetric complications related to defective placental

Although maternal serum sFlt-1 levels are known to be elevated in

function, including FGR.117,118 A systematic review estimating the

pre-eclamptic pregnancies, a large case–control study demonstrated

value of first-trimester 3D placental volume for the prediction of

that high levels of sFlt-1 at 10–14 weeks were actually associated

SGA found a detection rate of 24.7% at a 10% false-positive rate.119

101

with a slightly reduced risk of SGA (OR 0.92; 95% CI, 0.88–0.96).

Another parameter is the placental quotient, defined as the ratio of

Therefore, the sFlt-1:PlGF ratio test used to diagnose pre-eclampsia

the placental volume to the fetal crown–rump length. The placen-

should not be used in the first trimester as a screening test for FGR.106

tal quotient was reported to have a high negative predictive value
for perinatal complications but was not very useful when used

5.3 | Ultrasound markers

for screening of SGA in a low-risk population, with a sensitivity of
27.1%.120 The discriminatory ability of placental volume alone for
SGA appears to be modest, but may be integrated into a multivari-

Several ultrasound-based markers have been shown to be predictive

able screening model. However, the use of 3D placental volume as

of FGR, including uterine artery Doppler, placental morphology, and

a routine screening tool for FGR is limited by the need for proper

placental volumes. However, given their modest predictive accuracy,

equipment and training required to obtain these measurements in a

they cannot be recommended for universal screening for FGR.

reproducible manner.

Increased uterine artery resistance largely reflects a failure of
extravillous cytotrophoblast invasion and transformation of the spiral arteries and is associated with the development of pre-eclampsia

5.4 | Prediction models

and FGR due to maternal vascular malperfusion of the placenta.107
First- and second-trimester abnormal uterine artery Doppler

Currently there is no single screening test sufficiently predictive of

waveforms, defined as mean pulsatility index above the 95th per-

FGR to recommend routine clinical use. Investigations are underway

centile, have been shown to be associated with FGR.108-110 In a large

to combine various tests, but such prediction models have not been

prospective cohort study of 4610 nulliparous women, uterine artery

sufficiently validated in terms of outcomes studies and therefore

+0

pulsatility index at 11

+6

to 13 weeks predicted 60% of preterm and

must be considered investigative protocols at this time. In a pro-

17% of term SGA infants at a false-positive rate of 10%.111 Although

spective cohort of 4970 women, the combination of first-trimester

uterine artery Doppler shows promise, especially for the predic-

maternal serum PAPP-A, beta hCG, maternal blood pressure, and

tion of early-onset FGR, current evidence does not support routine

uterine artery Doppler performed in the first trimester had a detec-

screening with uterine artery Doppler for FGR in low- or high-risk

tion rate of 73% for early SGA (<34 weeks) but only 32% for late SGA

pregnancies.112

(≥34 weeks).19 A different model that included maternal character-

Sonographic evaluation of the placenta is a routine part of

istics, first-trimester blood pressure, uterine artery pulsatility index,

the obstetric ultrasound examination. A method for systematic

PlGF, and sFlt-1 was evaluated in a larger cohort of 9150 women
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and achieved a detection rate of 86% for early-onset FGR and 66%
19,121

for late-onset FGR, both at a false-positive rate of 10%.

the risk of FGR

130,131

In a recent meta-analysis of 45 trials that

In the

included 20 909 women at high risk of pre-eclampsia, the admin-

second trimester, the SCOPE consortium examined 5606 healthy

istration of aspirin starting at less than or equal to 16 weeks of

nulliparous women with singleton pregnancies and found that the

pregnancy reduced the risk of FGR by nearly half (RR 0.56; 95% CI,

combination of clinical risk factors, 15-week biomarkers (53 biomark-

0.44–0.70), with higher dosages of aspirin associated with a greater

ers were used), and 20-week ultrasound (fetal biometry and Doppler

reduction, favoring a dose of 100–150 mg.132 A second individual

studies of the umbilical and uterine arteries) had only a moderate

patient data meta-analysis also supported earlier initiation of aspirin

detection rate for SGA below the 10th percentile, with a positive

for the prevention of FGR, with an RR of 0.76 (95% CI, 0.61–0.94) for

predictive value of 32% and a negative predictive value of 91%.122

women randomized before 16 weeks versus an RR of 0.95 (95% CI,
0.84–1.08) for women randomized at 16 weeks or beyond.131 One

5.5 | Prevention of fetal growth restriction in highrisk populations

randomized trial found that evening but not morning administration
of aspirin is associated with reduction in the rate of pre-eclampsia
and FGR.133 However, it should be emphasized that most of the
available data on aspirin come from studies that focused on the pre-

5.5.1 | Lifestyle modifications

vention of pre-eclampsia as the primary outcome in women at high
risk of pre-eclampsia, with the prevention of FGR considered only as

Ideally, all women should plan their pregnancies, adopting a healthy

a secondary outcome. Furthermore, in the largest trial to date on the

lifestyle and optimizing any medical conditions and their body mass

use of aspirin for the prevention of pre-eclampsia (ASPRE trial), aspi-

index. The preconception period provides an opportunity for health

rin was not associated with a reduction in the risk of SGA below the

promotion with the aim of reducing accepted risk factors, including

10th, 5th, or 3rd percentile.130 However, we believe that given the

123

safety of aspirin and the overlap in the risk factors and pathogenesis

those associated with FGR.

Insufficient gestational weight gain has been associated with an

of pre-eclampsia and FGR, it is reasonable to recommend aspirin to

increased risk of FGR, especially in women with low body mass index

women at high risk of FGR, using the same regimen of aspirin used

(BMI, calculated as weight in kilograms divided by height in meters

for women at high risk of pre-eclampsia. Most international guide-

squared).124 Recognizing that these associations are only based on

lines recommend 100–150 mg aspirin to prevent FGR in women at

observational data, we still believe that it would be reasonable to

high risk.134

recommend monitoring of weight gain and informing women of the

The adjunct role of heparin in combination with aspirin to pre-

target weight gain range, as recommended by the 2009 Institute of

vent placenta-mediated complications in high-risk situations was

Medicine guidelines.125 These guidelines recommend a total gesta-

originally attributed to its anticoagulant properties and the specu-

tional weight gain of 12.5–18 kg (28–40 lb) for underweight women

lative prevention of placental thrombosis. However, in vitro and in

(BMI <18.5); 11.5–16 kg (25–35 lb) for the normal weight group (BMI

vivo data suggest heparins may have other biological properties

18.5–24.9); 7–11.5 kg (15–25 lb) for overweight women (BMI 25.0–

including anti-inflammatory, complement inhibition, and proan-

29.9); and 5–9 kg (11–20 lb) for obese women (BMI ≥30).126

giogenic activities.135-138 A study-level meta-analysis of six trials

Substance use, including smoking, alcohol, and illicit drugs, is

including 848 women showed that low-molecular-weight heparin

associated with low birth weight and increased perinatal morbidity

(LMWH) was associated with a reduction in the composite out-

and mortality.90 Interventions to promote smoking cessation during

come of pre-eclampsia, birth weight below the 10th percentile, pla-

pregnancy have been shown to result in a reduction in low birth

cental abruption, or pregnancy loss after 20 weeks (RR 0.52; 95%

127

weight (RR 0.81) and an increase in mean birth weight (+33 g).

CI, 0.32–0.86) with similar risk reduction for SGA below the 10th

Women should be advised that smoking cessation at any point in

and 5th percentiles. However, the higher-quality trials suggest no

gestation is of benefit, and that the greatest benefit is associated

treatment effect,139 and a subsequent individual patient data me-

128

with cessation before 15 weeks of pregnancy.

The risk of SGA

ta-analysis looking at the same composite outcome found no ben-

129

eficial effect of LMWH treatment (RR 0.64; 95% CI, 0.36–1.11).140

with alcohol intake is increased with as little as one drink per day.

Likewise, the enoxaparin for pre-eclampsia and intrauterine growth
restriction (EPPI) trial included women at high risk for placenta-me-

5.5.2 | Medical interventions

diated complications (with a high proportion of women with prior
FGR) and showed no difference in the rate of the composite out-

Most studies on early prevention of placental complications have

come (pre-eclampsia or SGA <5th percentile) between treated and

focused on pre-eclampsia, with the results often being extrapolated

nontreated women.141 Therefore, based on the most up-to-date ev-

to FGR due to the common pathophysiology. However, to date,

idence, LMWH cannot be recommended for the prevention of FGR

other than lifestyle modifications, no medical interventions to pre-

in women at high risk of placenta-mediated complications. Its use

vent FGR have been clearly established.

for the prevention of FGR should therefore be limited to research

Aspirin is recommended for women at increased risk of

settings, for example in women already on aspirin who are found to

pre-eclampsia, but there is some evidence that it may also reduce

have abnormal levels of angiogenic markers prior to fetal viability.142
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5.6 | Recommendations
FIGO recommends the following for prediction and prevention of fetal growth restriction (FGR)
Recommendation

Quality of
evidence

Strength of
recommendation

○

Strong

○

Strong

○

Strong

○

Strong

○

Strong

○

Strong

1. Women should undergo risk stratification for FGR (and other placenta-mediated complications) at the
time of the first-trimester antenatal visit using history-based (medical and obstetric) risk factors.

⊕⊕⊕

2. There is no evidence to support the routine use of biochemical markers for the prediction of FGR.
However, when such information is available as part of prenatal genetic screening for trisomy 21, it may
be reasonable to use this information for the purpose of risk stratification for FGR (and other placentamediated complications).

⊕⊕⊕

3. Ultrasound-based markers and multiparameter algorithms have only a moderate predictive accuracy for
FGR, and therefore currently cannot be recommended for universal screening.

⊕⊕⊕

4. Women at high risk for FGR should undergo close surveillance of fetal growth starting at 24–28 weeks.
LRS In low-resource settings, the frequency and type of monitoring may be limited by the availability
of obstetric ultrasound.

⊕⊕⊕

5. Women should be advised that smoking cessation and elimination of alcohol and illicit drugs can
decrease the risk of FGR.

⊕⊕⊕

6. Women should be advised on the association of insufficient gestational weight gain with FGR and be
informed regarding their target weight gain range.

⊕⊕⊕

7. There are insufficient data to recommend routine treatment with aspirin in all women at high risk of FGR.
Treatment with aspirin at a dose of 100–150 mg starting at 12–16 weeks may be considered in selected
cases such as women who are at high risk of pre-eclampsia or those with a history of placenta-mediated
FGR.

⊕⊕

8. Low-molecular-weight heparin is not recommended for the prevention of FGR in women at high risk of
FGR and its use should be limited to research settings.

⊕⊕⊕

○○
○

Weak

Strong
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6 | D E TEC TI O N O F FE TA L G ROW TH
R E S TR I C TI O N

and accurate results. A recent systematic review

165

found that the

Hadlock equation, based on three indices (HC, AC, and FL: Log10 we
ight = 1.326 − 0.00326*AC*FL + 0.0107*HC + 0.0438*AC + 0.158*F

Detection of FGR is based on the identification of a fetus that is

L), 2 provided the greatest accuracy. Since the accuracy of the various

smaller than expected for gestational age, through either physical

equations may vary between different populations, it may be rea-

examination (symphysis–fundal height, SFH) or ultrasound.

sonable for radiologists, sonographers, or care providers to choose
an equation that has been validated within their local population and
within the gestational age range in which it will be used. However, if

6.1 | Symphysis–fundal height

such information is not available—a very frequent scenario—it seems
reasonable to use the Hadlock equation as described above.

Measurement of SFH using a tape is a simple, inexpensive, and
widely used strategy to screen for FGR.143-146 SFH is measured with
the woman in a supine position using a nonelastic metric tape after
she has emptied her bladder. To decrease the interobserver vari-

6.3 | Is there a role for routine third-trimester
ultrasound to assess fetal growth?

ability, a standardized technique for measuring SFH should be followed.144,145 SFH is defined as the distance from the upper border

In many countries, measurement of SFH is the primary screening

of the symphysis pubis bone to the top of the uterine fundus.145

tool for FGR in low-risk pregnancies and ultrasound measurement of

SFH measured in centimeters between 24 and 38 weeks of ges-

fetal biometry is performed only when indicated on the basis of risk

tation approximates the gestational age.147 Numerous local charts

factors or abnormal SFH.134,143,172-174 However, this approach fails

148-156

with the recent addition of an

to identify the majority of FGR infants,146 a concerning finding given

145

international standard for SFH based on serial measurements.

that undetected FGR is associated with increased risk of adverse

However, the accuracy of SFH measurement in predicting SGA

perinatal outcome and stillbirth.53,175

are currently used worldwide,

(EFW <10th percentile) is limited, and there are no randomized con-

An alternative approach is to perform a routine third-trimester

trolled trials that compare SFH measurement with serial ultrasound

ultrasound for fetal weight estimation. However, a strategy for rou-

evaluation of fetal biometry.157 In a meta-analysis of 34 observa-

tine third-trimester ultrasound in low-risk pregnancies is not sup-

tional studies, SFH was reported to have a sensitivity of 58% and a

ported by available data and cannot be recommended.176-178

specificity of 87% for predicting birth weight below the 10th per-

A meta-analysis of 13 trials assessed the effect of routine

centile. There was marked heterogeneity between studies, mainly

sonographic weight estimation at more than 24 weeks of gestation

due to the use of different SFH charts.158 A single SFH meas-

on pregnancy outcomes in both unselected and low-risk pregnan-

urement at 32–34 weeks of pregnancy has been reported to be

cies.178 The authors found no association between routine sono-

approximately 65%–85% sensitive and 96% specific for detecting

graphic EFW and adverse pregnancy outcomes including perinatal

FGR.143 It is important to acknowledge that factors such as mater-

mortality, preterm birth, induction of labor, or cesarean section. In

nal obesity, uterine leiomyomas, and polyhydramnios may further

a recent randomized controlled trial of women with uncomplicated

144,159

limit the accuracy of SFH as a screening tool.

pregnancies, the use of serial (every 4 weeks) third-trimester ultrasound was superior to routine care in the detection of a composite
outcome of fetal growth or amniotic fluid abnormalities (RR 3.43;

6.2 | Sonographic fetal weight estimation

95% CI, 1.64–7.17).179 However, it is important to note that the incidence of maternal or fetal morbidity was not significantly different

Sonographic fetal biometry is the cornerstone for detection of fetal

between the groups. Similar results were reported by others.180

growth disorders. Standard fetal biometry includes assessment of

In contrast, the Pregnancy Outcome Prediction (POP) study pro-

head circumference (HC), biparietal diameter, abdominal circumfer-

spectively assessed 3977 women and compared the detection

ence (AC), and femur length (FL). Measurement of these biomet-

of SGA (birth weight <10th percentile) by routine ultrasound ver-

ric indices should be obtained by an experienced individual and in

sus clinically indicated ultrasound in the third trimester.181 The

160

a standardized manner, as has been previously described.

Fetal

detection rate of SGA was nearly tripled in the routine ultrasound

weight is estimated based on various combinations of the four bio-

group (57% vs 20%). The risk of neonatal morbidity was increased

metric indices described above, using one of many published equa-

only in the subset of SGA fetuses with fetal abdominal circumfer-

tions.161-165 The accuracy of most equations falls within the range of

ence growth velocity in the lowest decile (RR 3.9; 95% CI, 1.9–8.1),

±10%, and the error has been shown to be greater at the extremes of

emphasizing the importance of combined analysis of fetal biometry

fetal weight, and to be affected by factors such as fetal sex, presen-

and fetal growth velocity for better detection of fetuses at risk.182

tation, and plurality (greater in twin gestations).162-164,166-171 Several

Furthermore, it has been suggested that the prediction of FGR based

studies have compared the accuracy of various equations. Most

on routine third-trimester ultrasound can be improved by integrating

studies concluded that equations that are based on 3–4 biometric

EFW with additional biomarkers. A combined screening model that

indices (rather than only 1–2 indices) provide the most consistent

included maternal characteristics, third-trimester EFW and placental
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Doppler, and biochemical markers (PlGF and estriol) achieved better

women below or above certain height or weight, women with subop-

performance than EFW alone in the detection of FGR (77% vs 64%)

timal nutrition, low socioeconomic status, exposure to air pollution,

at a 10% false-positive rate.183

high altitude etc. Since growth standards include only low-risk un-

There are many conceptual explanations to support third-

complicated pregnancies, their distribution is usually narrower (i.e.

trimester ultrasound as it can assist in the diagnosis of clinically

the 10th and 90th percentiles are closer to the mean) compared with

significant 
findings other than FGR, including fetal malpresen-

growth references.

tation,184 disorders of amniotic fluid, and fetal anomalies,185,186

One important and practical aspect regarding the use of refer-

especially when combined with Doppler measurements and bio-

ence versus standard charts relates to the weight percentile thresh-

chemical markers.95,187-189 However, there is no evidence that this

old that should be used to trigger further evaluation for FGR. When

information improves outcomes when performed routinely in low-

using a growth reference, it is reasonable to use the 10th percen-

risk pregnancies.

tile for that purpose, as a considerable proportion of infants below
the10th percentile will be affected by pathology. In the case of

6.4 | Which growth chart should be used to
determine fetal weight percentile?

growth standard, however, using the same threshold of the 10th percentile would, per definition, identify 10% of the low-risk pregnancies as suspected for FGR, which is not practical. Therefore, when
using a growth standard, a lower threshold—such as the 5th or 3rd

The interpretation of sonographic EFW depends on gestational age

percentile—should be used to indicate further evaluation for FGR.

and is commonly classified as appropriate for gestational age, SGA,
or large for gestational age, based on the calculation of EFW percentile using one of the many available growth charts. The choice
of growth chart has been shown to have a considerable impact on

6.4.2 | Charts based on birth weight versus
sonographic fetal weight estimation

the proportion of fetuses classified as either SGA or large for gestational age.190,191 Over the past several years there has been an

A second important distinction is between growth charts that

ongoing debate regarding the optimal growth chart that should be

are based on birth weight versus those that are based on sono-

used, and numerous studies have compared the performance of

graphic EFW. Birth weight-based charts rely on cross-sectional

a wide variety of charts in different populations with conflicting

data of infant birth weights across the full range of gestational

results. Prior to further discussion of specific charts, it is important

ages, usually obtained from large databases. Different types of

to clarify the terminology and the types of charts that are currently

regression techniques are then used to calculate the mean and

available.

various percentiles of birth weight across gestation. These charts
are commonly used as they are easy to develop. However, their
main limitation is that infants born prematurely (before 37 weeks)

6.4.1 | Growth references versus growth standards

are more likely to be affected by placental dysfunction and to be
growth restricted. Therefore, these charts are likely to underes-

Growth references are descriptive charts that provide information

timate the optimal weight of fetuses during the preterm period,

on the distribution of weight of all newborns in a given population,

which in turn may lead to an underdiagnosis of FGR before

and as such they include both normal and complicated pregnancies.

37 weeks. This is illustrated in Figure 2, where the birth weight-

Although growth references are useful as they provide informa-

based chart of Alexander (USA)192 is compared with several ultra-

tion on the overall distribution of birth weight in the population,

sound-based charts.

their use for the purpose of antenatal detection of FGR may be

Therefore, it seems reasonable to prefer growth charts that are

challenging as they are affected by the rate of pathologies in the

based on sonographic EFW over those that are based on birth weight.

population. For example, in populations with a high rate of large

Ultrasound-based growth charts are more difficult and expensive to

fetuses (e.g. due to a high rate of obesity and diabetes), the refer-

develop, as they are usually based on data from prospective longi-

ence would be shifted upward. Similarly, in populations with a high

tudinal studies where women undergo several sonographic weight

rate of FGR (e.g. due to a high rate of malnutrition), the reference

estimations during pregnancy. However, these charts do not share

would be shifted downward.

the limitation of birth weight-based charts, described above, and

For that reason, it may be reasonable to prefer growth standards

are thus more likely to reflect the optimal fetal growth throughout

over growth references for the antenatal detection of FGR. Growth

pregnancy (Figure 2). Another reason why ultrasound-based charts

standards are prescriptive charts that are based only on low-risk

should be preferred is that the measure used during pregnancy

or uncomplicated pregnancies, and as such provide information on

to assess fetal growth is sonographic EFW; it is therefore more

what is the optimal fetal growth. There is variation between different

appropriate to compare it to charts based on the same measure

growth standards with regard to the definition of “low-risk” pregnan-

(i.e. sonographic EFW) rather than to charts based on birth weight.

cies; while some standards excluded women with pre-existing med-

Some of the commonly used ultrasound based charts are presented

ical conditions and pregnancy complications, others also excluded

in Figure 2.193
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published PRB/NICHD customized standard for African American

Hadlock
NICHDwhite
IG21
WHO
Alexander

women.199
According to the third approach, growth charts should be
adjusted not only for maternal race but also for other physiologic
factors that are thought to determine fetal growth potential, such
as maternal height, weight, parity, and fetal sex. One such example
is the Gestation Related Optimal Weight (GROW) software for cus-

2000

tomized growth percentiles. 200,201
At the other end of the spectrum is the individualized growth
assessment (IGA) approach, which is based on estimation of the

1500

growth potential of the individual fetus, calculated from the second-
trimester growth velocity of that fetus. These estimates are used
to generate individualized trajectories that are used to interpret

1000

fetal growth during the third trimester (https://igap.research.bcm.
edu). 202–204 While compelling, this approach requires earlier ultrasound exams during pregnancy, as well as appropriate software, and

500
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F I G U R E 2 Comparison of the 10th percentile curves of common
growth charts. Key: Hadlock: ultrasound-based chart193; NICHD,
National Institute of Child Health and Human Development
chart198; IG21, Intergrowth-21st chart196; WHO, World Health
Organization chart197 Alexander: birth weight-based chart.192
[Colour figure can be viewed at wileyonlinelibrary.com]

is therefore challenging at present for the purpose of FGR screening
in the general population, and especially in low-resource settings.

6.4.4 | Description of commonly available charts
The 10th percentile curves of some of the charts described above
are compared in Figure 2. The Hadlock chart (1991), one of the most
commonly used growth charts, is an ultrasound-based standard. It
is based on a cohort of 392 low-risk, primarily white women from

6.4.3 | Universal versus customized charts

Texas. The Alexander chart (1996) is based on over 3 million singleton live births in the USA and is included as an example of a birth

One final distinction is between universal and customized growth

weight-based reference to illustrate their limitation, which is the

charts, which represent a spectrum of approaches towards the

underestimation of optimal fetal growth during the preterm period.

similarity of the genetic growth potential of different fetuses

The goal of the Intergrowth-21st project (2014) was to develop

across the world. At one end of this spectrum there are universal

a universal ultrasound-based prescriptive growth chart. This was a

charts that are based on the assumption that under optimal condi-

prospective longitudinal study of 4321 low-risk women from eight

tions, all fetuses are expected to have the same growth potential,

centers located in eight high- and middle-income countries.194 The

irrespective of their country of origin or race and that the only

study had strict inclusion and exclusion criteria to ensure that partic-

reason for the differences currently observed between different

ipants were not exposed to environmental factors known to affect

countries or races are purely due to environmental factors, such

fetal growth, and it therefore aimed to reflect optimal fetal growth.

as malnutrition and environmental toxins. These ultrasound-based

Based on predetermined criteria, the authors concluded that the dif-

charts are developed through multicenter, multinational, prospec-

ferences between participants from different countries in measures

tive longitudinal studies, where data on sonographic fetal growth

of skeletal growth (crown–rump length and head circumference)

from multiple countries are pooled into a single international

were similar enough to justify pooling the data, and they therefore

universal chart. The best examples of such universal charts are

generated a single universal chart. No information was provided on

the recently published Intergrowth-21st194-196 and World Health

the differences between countries with respect to measures such

Organization (WHO) charts.197

as fetal weight estimation and abdominal circumference, which are

Others, however, believe that the variation in fetal growth

used in clinical practice to detect FGR and are known to be associ-

between countries and races is not solely the result of environ-

ated with adverse perinatal outcomes. Interestingly, there were con-

mental factors. Instead, it is suggested that genetic variation in

siderable differences in birth weight between infants from different

growth potential contributes to the observed differences in fetal

countries, even in this highly selected group of women free from

growth between race groups, and that race-specific charts should

the negative influence of environmental factors known to affect

therefore be preferred over universal charts. Examples of such

fetal growth. For example, the mean birth weight at term in India

race-specific charts are the National Institute of Child Health and

was 2.9 kg, which was approximately 600 g lower than the mean

Human Development (NICHD) charts which include separate charts

birth weight in the UK (3.5 kg).195 These differences have led some

198

for white, black, Hispanic, and Asian women,

and the recently

to question the validity of the pooled chart and of the hypothesis
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that underlies the Intergrowth-21st project. 205,206 As demonstrated

outcome. 217-219 Another criticism is that the GROW approach

in Figure 2, the 10th percentile of the Intergrowth-21st chart is

assumes that all fetuses follow the same growth trajectory (which

significantly lower throughout gestation than most other ultra-

is derived from the Hadlock chart)—an assumption that may not be

sound-based standards.

true. Finally, it has been suggested that the required adjustment

At around the same time, the results of the NICHD growth study
198

(2015) were published.

for multiple factors may be too complex for low-resource countries

The overall design of this study was similar

and, in that setting, a simple adjustment to only one factor—mean

to that of the Intergrowth-21st study. It was a prospective longitudi-

birth weight at 40 weeks in the local population—is as predictive

nal study of 2334 low-risk women from 12 centers in the USA. The

for adverse perinatal outcomes as the fully customized GROW

authors found substantial differences in fetal weight between dif-

charts. 220 It may thus be reasonable for care providers to compare

ferent race groups, and therefore developed separate race-specific

the performance of customized growth charts in their population

growth charts for white, black, Hispanic, and Asian women. The 10th

with that of noncustomized charts (as discussed below), especially

percentile of the NICHD growth chart for white women is included

in regions or countries with a mixed population where the benefit of

as an example in Figure 2.

customization is expected to be greatest.
197

The WHO fetal growth charts were published in 2017.

Similar

to the Intergrowth-21st project, this study aimed to develop a prescriptive universal chart to extend the previously published WHO
child growth standard

207

6.4.5 | How to choose the best chart

to the fetal period. The design of this

study was also similar to that of Intergrowth-21st—a prospective

The conflicting results and conclusions regarding the growth charts

longitudinal study of 1387 low-risk women from 10 centers in 10

described above have led to an ongoing debate about the best

high- and middle-income countries. Despite this, the results of the

approach (i.e. universal versus customized charts), as well as to con-

WHO study differed from those of Intergrowth-21st in two aspects.

siderable confusion among care providers over which chart they

First, the 10th percentile of the WHO chart is considerably higher

should be using in their local population.

than the Intergrowth-21st chart, and is in fact almost identical to the

The FIGO Safe Motherhood and Newborn Health Committee

10th percentile of the Hadlock standard (Figure 2). Second, unlike

recently published a position paper on the choice of reference

Intergrowth-21st, the investigators of the WHO study found sub-

charts for fetal growth and size at birth.3 In that paper, the commit-

stantial differences in fetal growth between the various countries,

tee reviewed in detail the commonly available charts and the avail-

and concluded that “…populations, even under optimal nutritional

able data on their predictive accuracy. The main conclusions were

conditions and environment, vary and that fetal growth varies and

as follows: (1) local or regional charts are likely to be best to iden-

should be considered when the WHO fetal growth charts or any

tify the 10th percentile of infants at highest risk, given that univer-

208

They expressed concern that use

sal charts such as Intergrowth-21st are likely to under detect SGA

of a universal chart carries a risk of misclassification of FGR, 209-211

fetuses in high-resource countries and, at the same time, over detect

and recommended that their chart should be adjusted in each coun-

SGA in low- and middle-income countries; (2) as an alternative, uni-

try to the local population.

versal standards such as Intergorwth-21st and WHO may be used

growth references are applied”.

The benefit of customized charts remains a matter of debate.

with locally adjusted thresholds (e.g. 3rd or 5th percentile in low-

The GROW software incorporates certain factors that are believed

or middle-income countries versus 15th or 20th percentile in high-

to determine fetal growth potential (maternal race, height, weight,

income countries) to avoid under or overdetection of SGA; and (3)

parity, and fetal sex) to calculate the predicted optimal (customized)

when assessing fetal size antenatally by ultrasound, fetal (i.e. ultra-

weight at 40 weeks for each individual fetus.

200,201

The customized

fetal growth curve is then determined retrospectively, based on a
proportionality growth function derived from the ultrasound-based
193

Hadlock standard.

sound-based) charts should be used rather than birth weight-based
charts. We fully endorse and support these recommendations.
Furthermore, we as well as others,160,208 believe that the deci-

The use of customized charts is appealing,

sion on which chart to use can be further based on a comparison of

especially in the setting of ethnically mixed populations where their

performance of the various charts in the population of interest, using

use has been shown to decrease over- and underestimation of FGR

a local data set. This can be achieved by the following approaches:

rates in certain race groups. 212 A large number of studies investi-

(1) statistical validation: finding the chart that matches best the dis-

gated the association of customized charts with adverse pregnancy

tribution of fetal weight in low-risk pregnancies in the local popu-

outcomes compared with other birth weight- and ultrasound-based

lation. That is, identifying the chart that when applied to the local

charts, with conflicting results. Several studies found that custom-

population yields weight percentiles that follow a normal distribu-

ized charts performed better at predicting stillbirth and adverse

tion centered at approximately the 50th percentile, and identifies

neonatal outcomes,66,201,211,213-216 while others found no benefit

approximately 10% of the low-risk population as being below the

and concluded that the benefit reported by others is merely because

10th percentile and above the 90th percentile, and approximately

they are based on an ultrasound-based chart and are thus more

5% of the population as being below the 5th percentile and above

likely to reflect optimal fetal growth, while the act of customization

the 95th percentile. An example of this approach is provided in

has a minimal contribution to the stronger association with adverse

Figure 3; (2) outcome-based validation: finding the chart for which
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F I G U R E 3 Illustration of the statistical validation of two charts in a local population. The left chart shows a good match to the population
of interest: the distribution of fetal weight percentiles based on this chart follows a normal distribution that is centered at the 50th
percentile, with approximately 10% of the population below the 10th and above the 90th percentile. The right chart shows a poor fit for
the population of interest as it is skewed to the right: it overdiagnoses fetuses as large for gestational age and underdiagnoses small-forgestational-age fetuses. [Colour figure can be viewed at wileyonlinelibrary.com]

the diagnosis of SGA has the best predictive value for adverse out-

10th%

comes related to FGR.. 211,221 While this approach seems compelling,

3000

interpretation of the predictive value of the different charts for addetection rate and false positive rate for adverse outcomes. 221 Thus,

2000

charts that are shifted upward (e.g. Hadlock, WHO) would have a
higher detection rate but also a high false-positive rate, while charts
that are shifted downward (e.g. Intergrowth-21st) would have a

Weight (g)

verse outcomes may be challenging, as there is a trade-off between

2500

1500

500

for SGA fetuses at risk of adverse outcomes (Figure 4). Finding the

0

requires careful consideration and should be based on a clear definition of the goals of screening.

6.5 | How to assess fetal growth in twin gestations
Twin fetuses grow more slowly than singletons, starting from
28–32 weeks of gestation onward. 222-225 At term, approximately
30%–50% of twins would be identified as SGA (EFW <10th percentile) using singleton growth standards. 223,226,227 The mechanisms
underlying the relative smallness of twins remain unclear. While

Adverse outcome
Stillbirth
Neonatal death
Neonatal morbidity
Asphyxia

1000

lower false-positive rate but would also have a lower detection rate
chart that provides the best balance between these two measures

10th%

22

24

26

28

Gesta

30

32

34

age (weeks)

36

38

40

F I G U R E 4 Illustration of the impact of the growth chart chosen
on the trade-off between detection rate and false-positive rate
of fetuses at risk of adverse outcome. Charts that are shifted
upward (light blue dotted line) will have a higher detection rate for
pregnancies at risk of adverse outcomes (red circles) but would also
have a higher false-positive rate (i.e. identify normal pregnancies
[green circle] as being at risk). In contrast, charts that are shifted
downward (dark blue solid line) will have a lower false-positive rate
(i.e. identify fewer normal pregnancies [green circle] as being at
risk) but will also have a lower detection rate for pregnancies at risk
of adverse outcomes (red circles). [Colour figure can be viewed at
wileyonlinelibrary.com]

some believe that this represents a pathological phenomenon due to
failure of the uteroplacental circulation to meet the demands of two

twins. If the slower growth of twins represents FGR, it would be rea-

fetuses (i.e. twins are more likely to be growth restricted due to the

sonable to use singleton growth standards to identify the small twin

same mechanism responsible for FGR in singletons), 224,228-230 others

fetus that, like SGA singletons, may be at increased risk for perinatal

suggest that this represents an early benign physiological adaptation

mortality and morbidity. However, if the relative smallness of twins

of twins to the “crowded” intrauterine environment in an effort to

is due to a benign adaptive mechanism, it may be preferable to use

delay the onset of labor (by decreasing uterine distension) and gain

twin-specific growth charts 223,232-235 to avoid overdiagnosis of FGR

maturation at the expense of size.

231

One important implication of

this question relates to the growth standard that should be used in

in twin gestations,63,227 which is associated with increased use of
resources, ultrasound exams, interventions, and patient anxiety.
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Most current guidelines do not provide clear recommendations

to have placental histopathological evidence of placental insuffi-

as to which type of charts should be used to monitor the growth of

ciency when compared with SGA singletons. 248,249 In another recent

143,236,237

twins,

while other guidelines specifically recommend the
238

study on the association between SGA and pre-eclampsia, it was

or twin-specific charts. 239 As a

found that in contrast to singletons, the diagnosis of SGA in twins

result, singleton-based standards are used by default in most centers

based on singleton charts was not associated with a greater risk of

to assess the growth of twins. However, recent data provide sup-

pre-eclampsia, while the association of SGA in twins diagnosed using

port to the hypothesis that the relative smallness of twins is a benign

twin-specific charts had the same magnitude of association with

adaptive mechanism and, therefore, for the use of twin-specific

pre-eclampsia to that observed between SGA and pre-eclampsia

charts. For example, several studies suggest that the slower growth

in singletons.63 Overall, these findings provide support to the

of twins is the result of differences in programming that is deter-

hypothesis that the relative smallness of twins is less likely to be the

mined as early as the first trimester.. 229,240-243 In addition, it was

result of placental insufficiency and, thus, less likely to reflect true

found that the use of twin-specific (versus singleton-based) charts

growth restriction. Based on that, we believe that it seems reason-

was associated with a marked decrease in the rate of twins classi-

able to use twin-specific charts for the assessment of fetal growth

fied as SGA, without affecting the detection rate of stillbirth, sug-

in twin gestations, as this has the potential to avoid overdiagnosis of

gesting that twin-specific charts can be used safely. 227,244,245 Similar

FGR and the consequences associated with this diagnosis. 246 This

findings were reported in studies that investigated the association

approach is supported by the recent guidelines of the International

between the type of chart used (twin versus singleton charts) and

Society of Ultrasound in Obstetrics and Gynecology (ISUOG). 239 Of

other outcomes such as perinatal complications and long-term mor-

note, the diagnosis of FGR in twin gestations should also take into

bidity. 246,247 Studies that investigated placental pathology findings

consideration intertwin size discordance, especially in the case of

reported that SGA twins (based on singleton charts) are less likely

monochorionic placentation. 250

use of singleton-based charts

6.6 | Recommendations
FIGO recommends the following for detection of fetal growth restriction (FGR)
Recommendation

Quality of
evidence

Strength of
recommendation

1. Symphysis–fundal height is a simple and inexpensive tool that can be used as the primary screening
strategy for FGR in low-risk pregnancies in both low- and high-resource settings.

⊕⊕⊕

○

Strong

2. There is no evidence to support routine third-trimester ultrasound for the detection of FGR, as this practice
has not been shown to be associated with improved perinatal outcomes.

⊕⊕⊕⊕

Strong

3. The choice of the equation used for sonographic fetal weight estimation may be based on validation within
the local population. If this information is not available, we recommend that the following equation of
Hadlock (based on head circumference [HC], abdominal circumference [AC], and femur length [FL]) should
be used 2: Log10 weight =1.326 – 0.00326*AC*FL + 0.0107*HC + 0.0438*AC + 0.158*FL

⊕⊕⊕

○

Strong

4. Growth standards that are based on sonographic fetal weight estimation should be preferred over growth
references and over charts that are based on birth weight.

⊕⊕⊕

○

Strong

5. We support the recommendation of the FIGO Safe Motherhood and Newborn Health Committee that local
or regional growth charts should be preferred over universal charts.3 Alternatively, universal standards
may be used with locally adjusted thresholds to avoid under- or overdetection of FGR.

⊕⊕⊕

○

Strong

6. The decision regarding which growth chart to use may be further guided by comparing the performance of
the various charts in the population of interest, using local data sets.

⊕⊕

7. Based on the available evidence it seems reasonable to use twin-specific charts for the assessment of fetal
growth in twin gestations as this has the potential to avoid overdiagnosis of FGR in this population.
8. In twin gestations, the diagnosis of FGR should also take into consideration intertwin size discordance,
especially in the case of monochorionic placentation.

○○

Weak

⊕⊕

○○

Weak

⊕⊕⊕⊕

Strong
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7 | W H AT K I N D O F I N V E S TI G ATI O N S
S H O U LD B E PE R FO R M E D W H E N FE TA L
G ROW TH R E S TR I C TI O N I S S U S PEC TE D?

first trimester, the earliest scan with a crown–rump length of at least

Once FGR is suspected, a systematic investigation should be per-

7.2 | Detailed anatomy scan

10 mm should be used. 268

formed aimed at identifying the underlying etiology for fetal smallness, with the most important reasons being constitutional SGA,

Detailed anatomy scan should be routinely performed when FGR

placental dysfunction, and fetal conditions such as genetic or infec-

is suspected, especially in cases of early-onset severe FGR. The

tious disorders. Establishing the most likely etiology is essential to

presence of major structural anomalies, soft sonographic markers,

allow for proper counseling, surveillance, and interventions. The

or disorders of amniotic fluid (e.g. polyhydramnios) may raise the

investigation should consist of detailed history, evaluation of screen-

possibility of chromosomal, subchromosomal, or single gene abnor-

ing test results for trisomy 21 and biochemical markers, detailed

malities as the cause of FGR. 269,270 The presence of very shortened

sonographic assessment for structural anomalies and Doppler stud-

fetal long bones (shorter than –2SD and especially –4SD below the

ies, and additional testing directed at genetic or infectious etiologies

mean) should raise the possibility of skeletal dysplasia and indicates

when they are suspected.

targeted genetic assessment. 271-273 Attention should also be given
to findings that are associated with congenital infections, especially
in women with a relevant history, as described above. Examples of

7.1 | Detailed history

such sonographic findings include small head circumference, ventriculomegaly, brain or liver calcifications, periventricular hypere-

A detailed maternal and family history is essential to correctly iden-

chogenicity, cortical brain malformations, echogenic bowel, hydrops,

tify the etiology of FGR. This should include information on maternal

or placentomegaly.40,274

age, racial/ethnic group, height and weight, nutritional status, socioeconomic status, medications, cigarette smoking and use of recreational drugs, chronic medical conditions, personal or family history

7.3 | Doppler studies

suggestive of thrombophilia, genetic disorders or consanguinity,
obstetric history including birth weight of previous children, and

Doppler assessment is an integral part of the diagnostic process and

confirmation of pregnancy dating by first-trimester ultrasound.143

management of FGR. The presence of abnormal Doppler findings in

Advanced maternal age has been associated with FGR, with risk

the uterine, umbilical, or middle cerebral arteries is highly suggestive

increasing for women over the age of 35 years.251,252 Maternal social

of placental dysfunction as the underlying etiology of FGR. A more

issues, low income, and domestic violence during pregnancy have

detailed description of the different types of Dopplers studies and

been shown to be associated with low birth weight.253,254 Poor nutri-

their application in monitoring and timing of delivery in pregnancies

tional status due to conditions such as celiac disease 255 and eating dis-

complicated by FGR is provided in section 8 (Management of FGR).

orders is a potentially treatable cause of FGR.256,257 Maternal smoking
is an important and potentially modifiable risk factor for FGR.

258,259

It should be noted that umbilical artery Doppler findings may
be normal in the early stages of placental FGR. Therefore, normal

History should also address the risk of congenital fetal infection

umbilical artery Doppler studies do not rule out placental dysfunc-

with cytomegalovirus, toxoplasmosis, syphilis, Zika virus, and var-

tion, and therefore serial monitoring is recommended in all cases of

icella-zoster virus. Relevant questions include a history of febrile

suspected FGR. 275,276 At the same time, abnormal umbilical artery

disease or rash in pregnancy or the periconceptional period, recent

Doppler is not pathognomonic of placental dysfunction, as certain

travel history to endemic areas (e.g. for Zika virus), and frequent ex-

genetic conditions (e.g. triploidy) may mimic early-onset placental

posure to young children (cytomegalovirus) or to domestic animals

FGR, including the presence of abnormal umbilical artery Doppler,

(toxoplasmosis).

most likely due to concomitant placental insufficiency secondary to

Accurate dating of pregnancy is essential for the correct inter-

the abnormal placental karyotype.34,277-279 In contrast to umbilical

pretation of estimated fetal size and to avoid a false diagnosis of

artery Doppler, uterine artery Doppler is less likely to be abnormal

FGR. Determining gestational age based on menstrual history is

among fetuses with FGR and abnormal karyotype, and should there-

often unreliable. 260,261 Therefore, with the exception of pregnan-

fore be considered to be more specific for primary placental FGR,

cies achieved by assisted reproductive technology, the crown–rump

especially in the presence of abnormal angiogenic markers in mater-

length measured at the time of first-trimester ultrasound is the most

nal blood.34,107,280

accurate method to date pregnancy, and establishes gestational
age with a precision of 5 days in 95% of cases. 262-265 Crown–rump
length is most accurate for the purpose of dating when in the range

7.4 | Additional testing

of 7–60 mm. 266,267 Therefore, confirmation of gestational age based
on first-trimester ultrasound (when available) should be the first step

Screening for congenital infections should be offered when FGR is

when FGR is suspected. If more than one scan is performed in the

suspected, especially in cases of early-onset FGR or when infection
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is possible based on history of ultrasound findings. Testing should

polyhydramnios), and the absence of obvious signs of placental

be focused on cytomegalovirus and toxoplasmosis, but may also

dysfunction such as abnormal uterine or umbilical artery Doppler.

include rubella, varicella, and syphilis in cases at high risk for these

In addition, women should be counselled about the risk of a genetic

infections. Testing for Zika virus and malaria should also be consid-

etiology even in the presence of “isolated” FGR (i.e. without associ-

ered in the relevant travel history or location context. However, it

ated fetal anomalies).37,270,283-285 A recent meta-analysis of 10 stud-

should be noted that interpretation of serology results may be chal-

ies found that in cases of isolated FGR, chromosomal microarray had

lenging due to limited specificity and cross-reactivity of some of the

an incremental yield of 4% (95% CI, 1%–6%) over karyotyping: 17 of

assays, especially when baseline serology results prior to pregnancy

376 fetuses with isolated FGR and normal karyotype had significant

or from early pregnancy are not available. 281 When fetal infection

findings in microarray, most commonly 22q11.2 duplication, Xp22.3

is highly suspected based on serology results or clinical findings,

deletion, and 7q11.23 deletion. The incremental yield of microar-

further testing should be offered by means of amniocentesis for

ray over karyotyping was even higher at 10% (95% CI, 6%–14%) in

the detection of viral DNA in the amniotic fluid using polymerase

the presence of associated fetal malformations.35 Based on these

chain reaction. In these cases, amniocentesis should be delayed until

data, it seems reasonable to offer amniocentesis with karyotype and

after 21 weeks of gestation and at least 6–8 weeks following the

microarray analysis (when available) to women with FGR, with the

estimated onset of maternal infection to minimize the risk of false-

decision based on factors such as ultrasound findings, gestational

negative results. 274,282

age, lack of evidence of placental dysfunction, and whether the re-

Genetic consultation and genetic testing by amniocentesis

sults of the amniocentesis would affect management. These data

should be offered to women with FGR, especially in cases of ear-

also suggest that the temptation to substitute amniocentesis by non-

ly-onset or severe FGR (<3rd percentile), co-presence of sono-

invasive prenatal testing (NIPT) using cell-free fetal DNA analysis in

graphic findings (such as structural anomalies, soft markers, or

this context should be strongly resisted.

7.5 | Recommendations
FIGO recommends the following for investigation of fetal growth restriction (FGR)
Quality of
evidence

Strength of
recommendation

1. Women with suspected FGR should undergo systematic assessment that includes the following: (1) detailed
history; (2) detailed sonographic assessment for structural anomalies, soft markers, and sonographic signs
related to fetal infection; (3) Doppler studies that include at least the umbilical artery and, when available,
also the uterine and middle cerebral arteries; and (4) maternal screening for relevant congenital infections,
which should be focused on cytomegalovirus and toxoplasmosis, but may also include rubella, herpes,
syphilis, malaria, and Zika virus in cases at high risk.
LRS The extent of investigation may be limited by available resources. Assessment should include
screening for infections such as malaria and Zika virus in endemic areas.

⊕⊕⊕⊕

Strong

2. Confirmation of gestational age should be the first step when FGR is suspected. With the exception of
pregnancies achieved by assisted reproductive technology, first-trimester crown–rump length is the most
accurate method to date pregnancy when in the range of 7–60 mm. If more than one scan is performed in
the first trimester, the earliest scan with a crown–rump length of at least 10 mm should be used.
LRS In low-resource settings, dating may need to be based on menstrual history or symphysis–fundal
height.

⊕⊕⊕⊕

Strong

3. Amniocentesis for karyotype (as well as microarray and polymerase chain reaction for infectious agents
when available) should be offered to women with suspected FGR, especially in cases with early-onset
severe (estimated fetal weight <3rd percentile) FGR, in the presence of sonographic findings associated
with genetic or infectious etiologies, no obvious signs of placental dysfunction, and when the findings are
likely to affect management.
LRS The availability of genetic testing may be limited by available resources.

⊕⊕⊕

○

Strong

Recommendation
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8 | M A N AG E M E NT O F PR EG N A N C I E S
W ITH FE TA L G ROW TH R E S TR I C TI O N

of fetal compromise are driven by placental blood flow resistance
in the umbilical artery, and therefore differ significantly between
early- and late-onset FGR. 286,289-291,298,299 The surveillance tests

Management of pregnancies with FGR depends in part on the results

that have been evaluated in the management of FGR pregnancies

of the investigation described in section 7. In cases of fetal abnor-

are described below.

malities (genetic or infectious) the management (expectant versus
pregnancy termination) should be individualized based on the nature
of the disorder, the expected prognosis, gestational age, parental

8.1.1 | Fetal movement counting

wishes, and local policies.
The most common underlying etiology of FGR is placental dys-

Fetal activity is established from the first trimester onward and

function. In early-onset FGR (<32 weeks), increased resistance in

as gestational age advances becomes organized into coordinated

umbilical artery Doppler is the primary rate-limiting step to sub-

behavioral states. Progressive fetal hypoxemia is accompanied by a

sequent deterioration of cardiovascular and biophysical param-

reduction of fetal activity that can be perceived most accurately by

eters.

286-292

The primary management challenge arises from the

the mother when she is lying down and paying focused attention to

risk of fetal deterioration and stillbirth in pregnancies undergoing

fetal movements. 305 Decreased fetal movement is often defined as

surveillance versus the neonatal morbidity and mortality associ-

less than 10 movements in 2 hours during focused maternal count-

ated with preterm delivery.68,293-297 In late-onset FGR (≥32 weeks),

ing. 306 Although reports on whether quality improvement tools

cardiovascular deterioration in response to fetal hypoxia is pre-

to promote awareness and management of reduced fetal move-

dominantly confined to the cerebral circulation with little umbilical

ments can effectively decrease the risk of stillbirth have been con-

artery Doppler changes. 289,291,292,298 Pregnancies complicated by

flicting, most of these interventions were focused on unselected

late-onset FGR are major contributors to adverse perinatal out-

populations rather than in pregnancies with suspected FGR. 307-309

come attributable to FGR because of misdiagnosis and challenges in

Given that fetal movement counting is a simple and inexpensive

detecting deterioration during fetal surveillance. 299,300

tool that may provide a safety net between scheduled outpatient

There is no effective antenatal treatment for placental dys-

monitoring visits, it seems reasonable to use movement counting

function and therefore once FGR has been identified, the principal

as an adjunct to monitoring in FGR. The mother should be provided

management steps are institution of fetal surveillance and deter-

with clear behavioral instructions and confirmatory monitoring

mination of appropriate thresholds for delivery. Perinatal outcome

should be performed for patients presenting with decreased fetal

in early-onset FGR is improved when pregnancies are managed in

movements. 305,308

a high-level fetal medicine and neonatology unit utilizing a uniform
management protocol. 301 Likewise, the optimal management setting for late-onset FGR is a unit that has access and experience in

8.1.2 | Fetal heart rate monitoring

interpretation of surveillance tests, together with an appropriate
level neonatal unit. The recommendations for monitoring, tim-

Fetal heart rate monitoring is universally recommended to moni-

ing and mode of delivery, and potential treatments for placenta-

tor pregnancies complicated with FGR.134,310-312 Antepartum car-

mediated FGR are described below and summarized in Table 1 and

diotocography (CTG), also known as a nonstress test (NST), can be

Figure 5.

performed as a standalone evaluation or in conjunction with measurement of amniotic fluid volume (modified biophysical profile), or a
five-component biophysical profile (BBP).

8.1 | Monitoring

Some heart rate characteristics reflect fetal oxygenation, gestational age, and maturational state of the nervous and cardiovas-

The primary goal of fetal monitoring is prevention of stillbirth by

cular systems. The normal heart rate baseline is between 110 and

detection of fetal deterioration that precedes irreversible compro-

160 beats per minute (bpm) and decreases with advancing gestation.

mise. To achieve this goal, monitoring tests need to be accurate

Periodic accelerations of fetal heart rate (FHR) usually coincide with

in identifying fetal risks that favor delivery and, for pregnancies

fetal movements, are observed from the early second trimester, and

where delivery thresholds are not met, follow-up monitoring needs

increase in magnitude and duration with advancing gestation. These

to be frequent enough to provide a safety net against unanticipated

are defined as increases in FHR over the baseline of at least 15 bpm

deterioration or stillbirth. Fetal surveillance tests include mater-

and 15 seconds’ duration. Two or more of these accelerations de-

nal monitoring of fetal movements, cardiotocography, ultrasound

fine a “reactive” pattern. Recognizing that the frequency of reactiv-

evaluation of amniotic fluid volume and fetal activity, and Doppler

ity increases from 50% at 24–28 weeks to 85% at 28–32 weeks of

ultrasound of the fetal arterial and venous circulations. With pro-

gestation, criteria of greater than or equal to 10 bpm amplitude and

gressive compromise, abnormal fetal activity and fetal heart rate

greater than 10 seconds’ duration are recommended at earlier ges-

patterns are observed, independent of gestational age at diagno-

tational ages.313-316 A “nonreactive” FHR pattern is one that does

sis of FGR.

288,292,302-304

In contrast, cardiovascular manifestations

not display accelerations over an observation period of 40 minutes.
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TA B L E 1 Recommendations for monitoring, timing, and mode of delivery in cases with suspected fetal growth restriction.
Findings

Risk of stillbirth

Suggested monitoringa

Timing and mode of deliveryb

SGA (EFW at 3rd–9th
percentile, normal fluid and
Doppler studies)

Low

• Doppler (UA, MCA) every
1–2 weeks
• Growth every 2 weeks
• At ≥37 weeks consider BPP/NST
1–2 times per weekc

• 37–39 weeks
• Mode of delivery: induction

Uncomplicated FGR at <3rd
percentile (normal fluid
and Doppler studies)

Low

• Doppler (UA, MCA) 1–2 times per
week
• Growth every 2 weeks
• At ≥37 weeks consider BPP/NST
1–2 times per weekc

• 36–38 weeks
• Mode of delivery: induction

FGR with mild abnormalities:
• Early Doppler changes:
a. UA PI >95th percentile,
or
b. MCA PI <5th percentile,
or
c. CPR <5th percentile, or
d. UtA PI >95th percentile
• Oligohydramnios
• Suboptimal interval growth
• Suspected pre-eclampsia

Low

• Consider inpatient monitoring
• Consider steroids for fetal lung
maturation
• BPP/NST 1–2 times per week
• Doppler (UA, MCA, DV) 1–2
times per week
• Growth every 2 weeks

• 34–37 weeks
• Mode of delivery: cesarean
section or induction

FGR with umbilical artery
AEDV/REDV

• Overall risk of stillbirth:332
a. AEDV: 6.8%, OR 3.6 [2.3–5.6]
b. REDV: 19%, OR 7.3 [4.6–11.4]
• Risk of stillbirth with strict
monitoring protocol with a safety
net343:
a. AEDV: 0%–1%
b. REDV: 1%–2%
• Median time for deterioration:
a. AEDV: 5 days
b. REDV: 2 days

•
•
•
•

Inpatient monitoring
Steroids for fetal lung maturation
BPP/NST 1–2 times per day
Doppler (UA, MCA, DV) every
1–2 days
• Growth every 2 weeks

• AEDV: 32–34 weeksd
• REDV: 30–32 weeksd
• Mode of delivery: cesarean
section

FGR with abnormal ductus
venosus Doppler

• Overall risk of stillbirth332: 20%,
OR 11.6 (6.3–19.7)
• Risk of stillbirth with strict
monitoring protocol with a safety
net:343
a. Elevated DV PIV: 2%
b. Absent-reverse a-wave in DV:
4%

•
•
•
•

• 26–30 weeksd
• Mode of delivery: cesarean
delivery

Inpatient monitoring
Steroids for fetal lung maturation
BPP/NST twice per day
Daily Doppler

Abbreviations: AEDV/REDV, absent or reversed diastolic velocity in the umbilical artery; BPP, biophysical profile; CPR, cerebroplacental ratio; DV,
ductus venosus; FGR, fetal growth restriction; MCA, middle cerebral artery; NST, nonstress test; OR, odds ratio; PI, pulsatility index; PIV, pulsatility
index for veins; SGA, small for gestational age; UA, umbilical artery; UtA, uterine artery.
a

Monitoring should be based on integration of multiple modalities (Doppler, BPP, NST).

b

Absolute indications for delivery at any gestational age and birth weight combination that are considered to be viable include: BPP or NST
abnormalities or severe pre-eclampsia with uncontrolled hypertension or end-organ damage (section 8.2.3). In addition, timing of delivery should be
individualized based on factors such as parental decision regarding threshold for intervention.

c
There is lack of evidence on the appropriate test to predict the risk of fetal deterioration and on the optimal monitoring strategy in cases of
uncomplicated SGA fetuses, especially at term. Given this, there are differences in practice in various regions of the world regarding use of BPP/NST
for fetal monitoring in this context, and some of the authors of these guidelines do not use BPP or NST for monitoring of fetuses with uncomplicated
SGA as long as Doppler studies are normal. We suggest that the decision regarding use of BPP/NST should be based on local practices, the risk
profile of the local population, and the available resources in each particular setting.
d

Timing should be individualized based on local neonatal outcomes. Before 26 weeks, careful and shared decision making with the parents and
neonatology team is recommended.

In addition to reactivity, FHR patterns display “variability”—the

sympathetic–parasympathetic activity, secondary to diminished

average oscillations in the FHR signal, evaluated in bpm in 1-min-

brainstem oxygenation.

ute windows. Reduced variability appears later than absent reactiv-

The FHR pattern reflects fetal oxygenation and acid-base sta-

ity in the process of progressive fetal hypoxia. It reflects reduced

tus at the time of evaluation but does not predict deterioration
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F I G U R E 5 Delivery criteria for fetal growth restriction. Delivery criteria are based on monitoring with umbilical artery, ductus venosus,
and middle cerebral artery Doppler at specified gestational ages with traditional nonstress testing or computerized CTG (cCTG) if available.
Abbreviations: NICU, neonatal intensive care unit; FHR, fetal heart rate; CTG, cardiotocogram; STV, short-term variation; ms, milliseconds;
EFW, estimated fetal weight; PI, pulsatility index. [Colour figure can be viewed at wileyonlinelibrary.com]

in FGR. In unselected pregnancies the rate of stillbirth in the

interpretation of CTG/NST tracings.318 cCTG evaluates FHR param-

week following a reactive CTG/NST is 1.9/1000 (negative pre-

eters such as baseline, accelerations, decelerations, and variability

dictive rate of 99.8%). 317 Without any additional information, the

in an objective and quantifiable way. The Sonicaid cCTG system

empirically recommended minimum frequency is twice weekly

(Huntleigh Healthcare, Cardiff, UK) provides the parameter “short-

CTG/NST. The frequency may be increased when evaluation of

term variation” (STV) in milliseconds, while others quantify variabil-

amniotic fluid or Doppler parameters indicate a more advanced

ity in a more traditional way in bpm.319 In contrast to visual FHR

degree of fetal compromise and delivery criteria have not yet

analysis, cCTG decreases observer variability and allows longitudinal

been met. A nonreactive CTG/NST has low specificity for hypoxia

numerical analysis of variability.320

and requires additional tests to determine fetal status and dis-

FHR variability increases with gestational age; after 29 weeks of

tinguish FHR pattern variations caused by fetal behavior, while

gestation, below 4.0 ms or below 3.0 ms meet criteria for reduced

reduced variability is a much stronger predictor of central ner-

or very low STV, respectively.321 Before 29 weeks of gestation, STV

vous system hypoxia.

below 3.5 ms is considered reduced, and below 2.6 ms is considered
very low. STV below 3 ms has a 77% positive predictive value for
fetal acidemia.322,323

8.1.3 | Computerized fetal heart rate monitoring

Similar to CTG/NST, cCTG does not predict fetal deterioration. In
early-onset FGR the daily risks for abnormal STV are 4%–5% but are

Some professional societies recommend computerized fetal heart

unpredictable by additional monitoring tests. Accordingly, CTG/NST

rate monitoring (cCTG) as the preferred modality to analyze CTG/

or cCTG monitoring needs to be performed more frequently than

NST tracings.134,308 Inconsistency in visual assessment, particularly

Doppler assessments. In patients receiving inpatient monitoring, a

FHR variability, is a major contributor to interobserver variations in

minimum frequency of daily cCTG/CTG/NST is recommended.320
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8.1.4 | Ultrasound measurement of amniotic
fluid volume

33

The BPP is a more accurate predictor of fetal acid-base status at
the time of testing than CTG/NST, with a similar accuracy as cCTG.
Therefore, a five-component BPP can be used to clarify fetal acid-

Professional societies do not recommend inclusion of isolated

base status when a nonreactive CTG/NST is obtained. The frequency

amniotic fluid volume assessment into management decisions for

of BPP testing is guided by the same principles as timing of fetal heart

FGR. A decrease in amniotic fluid volume can occur as a result of

rate testing.

fetal oliguria in response to progressive placental dysfunction and
hypoxia, as well as rupture of membranes. 287,288,324 Accordingly,
additional evaluation is required to determine the significance of

8.1.6 | Umbilical artery Doppler

decreased amniotic fluid volume. Oligohydramnios can be defined
as an ultrasound measured four-quadrant amniotic fluid index below

Umbilical artery Doppler is universally recommended for monitoring

or equal to 5 cm, or a maximum vertical amniotic fluid pocket below

of FGR because it assesses the hemodynamic aspect of placental

or equal to 2 cm.325 Use of the latter reduces overdiagnosis of oligo-

dysfunction.134,143,308,310 It is estimated that approximately one-third

hydramnios and is preferred. Oligohydramnios is associated with an

of the villous circulation needs to be damaged before a decrease in

increased rate of intrapartum FHR abnormalities, need for cesarean

umbilical artery end-diastolic velocity occurs. Absent or reversed

section, and low 5-minute Apgar scores, but not acidosis at birth.326

umbilical artery end-diastolic velocity corresponds to malperfusion
of 50%–70% of the villous vascular tree.328 Because elevated villous
blood flow resistance is predominantly associated with the placental

8.1.5 | Biophysical profile scoring

pathology found in early-onset FGR, umbilical artery Doppler does
not reliably predict outcome in late-onset FGR.329-331

Biophysical profile (BPP) scoring is not universally recommended as

The umbilical artery Doppler waveform can be quantified using

the primary surveillance tool for FGR and is predominantly utilized

the pulsatility index, or by visual classification of end-diastolic veloc-

in Canada and North America where the concept was first devel-

ity as absent (AEDV) or reversed (REDV). With increasing degrees

oped for fetal surveillance in the later part of the third trimester. The

of placental blood flow resistance, an abnormal umbilical artery

modified BPP refers to combined use of the CTG/NST as a short-

waveform is defined as either having an elevated pulsatility index,

term indicator of fetal acid-base balance and the maximum amniotic

AEDV, or REDV. The degree of placental blood flow resistance ele-

fluid pocket as an indicator of long-term placental function.327 The

vation is the primary factor determining the rate of clinical progres-

five-component BPP comprises fetal breathing movements, gross

sion and the associated risk for fetal deterioration and stillbirth in

body movements, and tone, in addition to CTG/NST and maximum

early-onset-FGR. 286,289,291,292 When the umbilical artery pulsatil-

amniotic fluid pocket, and therefore includes four indicators of

ity index is elevated but end-diastolic forward flow is still present,

short-term acid-base balance.301

the median time interval to additional surveillance abnormalities is

The modified BPP is considered abnormal when either the CTG/

2 weeks. Once AEDV occurs, cardiovascular deterioration advances

NST is nonreactive, or the maximum amniotic fluid pocket is below

after a median of 5 days and the weighted odds ratio for stillbirth is

2 cm. The most common reason for an abnormal modified BPP is a

3.6 (2.3–5.6). 286,291,332 When REDV occurs, the median interval for

nonreactive CTG/NST, requiring additional ultrasound observation

further fetal deterioration is 2 days and the weighted odds ratio for

to complete a five-component BPP and determine fetal acid-base

stillbirth is 7.3 (4.6–11.4). 291,331

balance. The BPP is scored over a 30-minute ultrasound observation

In patients with normal umbilical artery Doppler, the recom-

period of the fetus. Fetal breathing movements are considered pres-

mended frequency to repeat Doppler monitoring ranges from weekly

ent if one or more episodes of 30 seconds of breathing or hiccups

to every other week. However, when AEDV develops, Doppler sur-

are observed. Fetal body movement is present when three or more

veillance is recommended at minimum twice weekly, and for REDV

discrete body or limb movements are observed. Fetal tone is pres-

at least three times weekly unless delivery criteria have been met.

ent when one or more episodes of extension and flexion of the fetal
extremities are observed. Each component of the BPP receives a score
of 2 for its presence and 0 for its absence. Scores of 8–10, 6, and 4 or

8.1.7 | Cerebral artery Doppler

less are considered normal, equivocal, and abnormal, respectively.
In unselected pregnancies, the rate of stillbirth in the week fol-

The majority of professional societies now recommend middle cer-

lowing a normal modified or five-component BPP is 0.8/1000 (neg-

ebral artery Doppler for monitoring in late-onset FGR. Concurrent

ative predictive rate >99.9%). FGR fetuses show a sequential loss of

measurement of the umbilical artery and middle cerebral artery

heart rate reactivity, breathing movements, gross body movement,

pulsatility index allows calculation of the cerebroplacental Doppler

and tone with decrease in pH.

287,288,301,302

In FGR pregnancies, an

ratio. Both the cerebroplacental ratio and middle cerebral artery

abnormal BPP (score of 4 or less) is associated with an umbilical

pulsatility index decrease as a hemodynamic response to fetal

artery pH of less than 7.20, with sensitivity increasing to 100% at a

hypoxemia and therefore reflect placental dysfunction, even in

score of 0/10.301,302,319

those pregnancies where the villous blood flow resistance is not
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elevated enough to produce an abnormal umbilical artery pulsatility

heavily influenced by gestational age. A robust plan is essential,

index. Approximately 20% of term SGA fetuses with normal umbili-

since expectant management with ongoing monitoring, particularly

cal artery Doppler have a decreased middle cerebral artery pulsatil-

in the setting of early-onset FGR, can result in a three to five-fold

ity index, which is associated with a higher rate of cesarean section

increased stillbirth rate when compared with immediate delivery,

for intrapartum distress, poor neonatal transition, and adverse

depending on the degree of cardiovascular compromise that is tol-

The cerebroplacental Doppler ratio

erated before triggering delivery. 294,342,343 The optimal monitoring

is more closely related to fetal hypoxia than its individual compo-

frequency in FGR has not been determined due to the varying cir-

nents,336 but has a similar predictive accuracy for perinatal death,

cumstances of gestational age and severity of FGR. A combination of

fetal distress, or poor neonatal transition as the umbilical artery pul-

surveillance modalities is needed to accurately determine fetal acid-

developmental outcome.

satility index.

333-335
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base status at the time of testing, as well as allowing anticipation

Cardiovascular deterioration in late-onset FGR is characterized

of future deterioration. 289-292,298,344 The accurate prediction of fetal

by abnormal cerebral artery Doppler. Therefore, an important role of

acid-base status is required to prevent unnecessary intervention and

middle cerebral artery Doppler is to provide an estimate of perinatal

nonindicated delivery. The anticipation of deterioration informs sub-

risk in patients with normal umbilical artery Doppler.

292,331

Because

sequent monitoring intervals that provide a safety net against unan-

of the higher risk for adverse outcome within 1 week of a decrease in

ticipated fetal acidosis and asphyxia. The combination of biophysical

middle cerebral artery pulsatility index, it is recommended to utilize

(CTG/NST, cCTG, BPP) and cardiovascular parameters (umbilical

at least twice weekly surveillance in this setting.

artery, middle cerebral artery, and ductus venosus Doppler) is considered a robust approach for FGR surveillance. Among these modalities, the combination of CTG/NST and umbilical artery Doppler

8.1.8 | Ductus venosus Doppler

is universally recommended.
There is good evidence that umbilical artery Doppler offers

The few professional societies that recommend ductus venosus

sufficient information to determine monitoring frequency in early-

Doppler evaluation specify that it should be performed in special-

onset FGR. Although middle cerebral artery Doppler could provide

ized centers that have expertise in the comprehensive perinatal

additional information in those late-onset FGR pregnancies with

management of early-onset FGR.312 The relative forward flow in

normal umbilical artery Doppler, this practice has not been evalu-

atrial systole in the ductus venosus decreases with worsening pla-

ated. 292,328,329 Based on observational data in term FGR with nor-

cental function or reduced fetal cardiac function, leading to an

mal umbilical artery Doppler, the approximate interval to stillbirth

increase in the pulsatility index for veins, absent, or reversal of the

in patients with abnormal middle cerebral artery Doppler is 4 days,

a-wave. 286,288,291,292,338

suggesting the need for twice weekly CTG/NST monitoring. In

Abnormal ductus venosus Doppler is primarily observed in

the absence of further evidence on the clinical benefit of middle

early-onset FGR and can provide an estimate of fetal acid-base bal-

cerebral artery Doppler, twice weekly CTG/NST monitoring in FGR

ance and the risk of stillbirth. The odds ratio of absent or reversed

after 32 weeks of gestation in patients with normal umbilical artery

atrial systolic velocity for an umbilical artery pH less than 7.20 at

Doppler provides the same safety net (Table 1).

birth is 4.4 (1.2–17.2).

339,340

The weighted odds ratio of absent or

When umbilical artery pulsatility index is elevated, weekly

reversed ductus venosus atrial systolic velocity for fetal death is 11.6

Doppler is suggested, and when there is AEDV or REDV, more fre-

(6.3–19.7).331

quent assessment is recommended (Table 1). In early-onset FGR with

Abnormal ductus venosus Doppler also predicts fetal

AEDV or REDV, the risk of stillbirth increases when the ductus veno-

decompensation to an abnormal BPP, reduced variability on cCTG,

sus Doppler or the CTG/NST patterns become abnormal. 292,319,340

or stillbirth. In fetuses with elevated ductus venosus pulsatility

However, there is currently no evidence that adjusting the timing of

index for veins but forward flow during atrial systole, the median

monitoring based on ductus venosus Doppler improves outcome. In

interval to progressive venous Doppler deterioration can be as

patients with AEDV the stillbirth rate is 0%–1% when at least once

short as 2 days.

291

In patients that do not yet meet delivery cri-

daily CTG/NST, cCTG, or BPP is performed with predefined delivery

teria, ductus venosus Doppler is recommended at minimum twice

criteria.341,342 When monitoring is continued to allow for an increase

weekly in patients with AEDV and three times weekly when REDV

in the ductus venosus pulsatility index for veins, the stillbirth rate

is observed. 286,291,292,341 When ductus venosus Doppler indices

is 2%, and 11% of deliveries occur for abnormal STV, 19% for an

increase as a new finding, the frequency of monitoring needs to

abnormal BPP, and 22% for FHR decelerations.304,342 When moni-

be increased further.

toring is continued in anticipation of reversal of the ductus venosus
a-wave velocity, the stillbirth rate is 4%, and 20% of deliveries occur
for abnormal STV, 29% for an abnormal BPP, and 31% for FHR decel-

8.1.9 | Surveillance strategy

erations (Table 1).342,345 This indicates that with ongoing monitoring
the risk of FHR abnormalities or an abnormal BPP requiring delivery

Monitoring in FGR pregnancies is intended to prevent fetal com-

cannot be predicted by the ductus venosus Doppler.319,346 Based on

promise or stillbirth, and the choice of tests and their timing is

the regional pattern of practice, this indicates that in patients who
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are admitted for AEDV, the minimum frequency of CTG/NST or BPP
should be daily and more frequent with REDV (Table 1).

319
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and neurodevelopment by delaying delivery until 34–36 weeks. The
increase in stillbirth rate in undelivered fetuses increasingly favors
delivery from 36 weeks onward.

8.2 | Timing of delivery

Timing of delivery in FGR has been evaluated in three randomized trials. The growth restriction intervention trial (GRIT) randomized pregnancies that had abnormal fetal biometry and umbilical

The timing of delivery in FGR is determined by gestational age,

artery Doppler studies performed as part of clinical management

severity of FGR, findings of fetal monitoring tests, and maternal

into immediate delivery after completion of a course of steroids

factors such as pre-eclampsia (Table 1 and Figure 5). Delivery in-

versus delivery when the managing physician was no longer com-

dications can be considered as absolute if they are independent of

fortable with conservative management. 294,295 The monitoring pro-

gestational age, and relative if the threshold to deliver based on the

tocol and delivery criteria were not specified. The trial demonstrated

surveillance findings varies across gestational age.

that, in the absence of specific criteria, either management approach
resulted in the same perinatal outcome. Delaying delivery increased
the risk of stillbirth, while earlier delivery resulted in a higher degree

8.2.1 | Gestational age-related risks in fetal growth
restriction

of prematurity-related complications that either led to neonatal
death or an increased risk of developmental delay.
The disproportionate intrauterine growth intervention trial at

With advancing gestational age there are several important changes

term (DIGITAT) randomized SGA fetuses by several biometry crite-

in the relative risks of delivery versus ongoing surveillance that

ria, independent of the umbilical artery Doppler pattern, to induction

define the delivery thresholds.

or expectant monitoring between 36 and 41 weeks of gestation.347

From 24–28 weeks of gestation each day of pregnancy pro-

The study demonstrated that, while elective induction did not affect

longation results in an estimated 2% decrease in neonatal death,

neonatal or obstetric outcomes, deliveries prior to 38 weeks resulted

as well as major neonatal complications including bronchopul-

in a higher rate of admissions to the neonatal intensive care unit.

monary dysplasia, high-grade intraventricular hemorrhage, and

These trials demonstrate that the relative risk for neonatal com-

surgical necrotizing enterocolitis. The impact of prematurity,

plications requires definitive delivery indications until 38 weeks of

neonatal weight below 500 g, challenging resuscitation, and

gestation. After that time, delivery for indication of FGR is likely to

decreased tolerance for low Apgar scores results in average neo-

prevent stillbirth in ongoing pregnancies. The continuous decrease

natal survival rates below 50% and intact survival below 50% until

in neonatal risks requires that delivery indications at early ges-

26 weeks. 68,298,345,346

tational ages occur at a higher threshold for fetal risks than after

Between 28 and 30 weeks of gestation the daily increment in

30–32 weeks.

survival is approximately 0.7%. After 30 weeks, neonatal survival
rates exceed 90%,68,296,297 and there is a significant decrease in
major neonatal complications from approximately 35% at 30 weeks
to less than 10% at 34 weeks, as well as a decrease in the risk of neu-

8.2.3 | Absolute delivery criteria for fetal growth
restriction (independent of gestational age)

rodevelopmental delay for neonates delivered after this time. FGR
infants delivered prior to 30 weeks have a three-fold higher rate of

Absolute delivery criteria are findings associated with important

developmental abnormalities and an up to eight-fold increased rate

health risks to the mother or fetus, and therefore require delivery

10,295

of cerebral palsy.

without consideration of gestational age (Figure 5).

From 34–38 weeks of gestation neonates are more likely to

The fetal biophysical variables are strongly influenced by oxygen

require admission to the intensive care nursery but have reduced

tension in the regulatory centers. A 30-minute BBP score of 0 or 2,

risks of major neonatal complications.347,348 In SGA fetuses that

or a 60-minute score of 4 indicates a prelabor fetal pH of less than

remain undelivered after 38 weeks, the risk of stillbirth doubles

7.20 and requires delivery to prevent fetal demise.

every week and reaches 60/10 000 for pregnancies that continue
beyond the due date.349,350

Repetitive FHR decelerations, a sinusoidal heart rate, absent
variability with recurrent late decelerations, or bradycardia predict
fetal acidemia and poor perinatal outcome and require delivery if the
causative stimulus cannot be removed. When cCTG is used, a short-

8.2.2 | Gestational age-related
management strategy

term variation below 2.6 ms is below the 5th percentile irrespective
of gestational age and requires delivery for its strong association
with fetal acidemia.

The balance between fetal and neonatal risks defines the pre-

Maternal pre-eclampsia with severe features complicates up to

dominant management strategy at different gestational epochs.

30% of FGR pregnancies, with a higher proportion in early-onset

Accordingly, the goal of management shifts from gaining fetal viability

FGR. In the absence of effective treatment other than delivery,

at 26 weeks to a graded improvement in survival, neonatal morbidity,

pre-eclampsia with uncontrolled severe hypertension, HELLP
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syndrome (hemolysis, elevated liver enzyme levels, and low plate-

Therefore, it is recommended that in FGR fetuses with nonreassur-

lets), or other evidence of end-organ damage (e.g. oliguria or acute

ing CTG/NST not yet meeting the criteria for delivery, a BPP is com-

renal injury other than proteinuria, pulmonary edema, or eclampsia)

pleted to establish fetal status. If the expertise is not available to

requires delivery (Figure 5).

perform a BPP, prolongation of the CTG/NST or increase in testing
frequency may be required to determine if delivery is necessary.
Optimal delivery criteria for FGR presenting after 32 weeks of

8.2.4 | Relative delivery criteria for fetal growth
restriction (adjusted for gestational age)

gestation have not been evaluated in a randomized trial and are
based on expert consensus. Table 1 and Figure 5 summarize the
management approaches and recommendations for delivery. When

The trial of umbilical and fetal flow in Europe (TRUFFLE) evaluated

local neonatal outcomes are consistently more favorable for FGR

two monitoring strategies and specific delivery criteria in early-

neonates, relative delivery indications may be applied at earlier ges-

onset FGR, with survival without neurodevelopmental impairment at

tational ages than indicated. For example, improved neonatal sur-

2 years of age as the primary outcome.343 Monitoring with cCTG and

vival may justify delivery for REDV from 30 weeks onward.

umbilical artery Doppler was universal in all patients, while ductus
venosus Doppler was only added in two study arms. Patients were
randomized to one of three specific delivery criteria: (1) abnormal
cCTG STV; (2) mild ductus venosus abnormalities; and (3) severe duc-

8.3 | Mode of delivery and intrapartum
considerations

tus venosus abnormalities with absence or reversal of the a-wave.
Because patients with ductus venosus Doppler monitoring also had

FGR in itself is not an indication for cesarean section. However, pri-

FHR monitoring, safety net delivery criteria based on cCTG were also

mary cesarean section may be considered in selected cases of severe

applied in these groups. These included STV below 2.6 ms irrespec-

FGR where the likelihood of successful vaginal delivery is low.

tive of gestational age and below 3.0 ms from 29 weeks onward. In

Fetuses with placenta-mediated FGR are less likely to tolerate

addition, umbilical artery Doppler findings were utilized as relative

the stress associated with labor and are at increased risk of requiring

delivery criteria from 30 weeks onward for REDV and 32 weeks

intrapartum urgent cesarean section for nonreassuring FHR tracing.

onward for AEDV. The choice of these thresholds is supported by a

Therefore, in certain cases of FGR, a trial of labor is highly unlikely to

recent meta-analysis that found that in undelivered FGR pregnancies,

be successful and might be associated with fetal risks to the extent

umbilical artery REDV has a 19% stillbirth rate, which exceeds mortal-

that a primary cesarean section should be preferred. This depends

ity for neonates delivered from 30 weeks onward, while AEDV carries

on multiple factors including gestational age, severity of FGR,

a 6.8% stillbirth risk, which favors delivery due to lower neonatal mor-

Doppler changes, associated pre-eclampsia, parity, cervical Bishop

tality from 32 weeks onward (Table 1 and Figure 1).

332

score, and patient preference (Table 1).

The TRUFFLE study demonstrated that a predefined manage-

In cases of early-onset FGR the main goal is to prolong preg-

ment strategy produces better outcomes than expected in all FGR

nancy and maximize fetal maturation by means of expectant man-

pregnancies.343 The primary endpoint was less frequently observed

agement under close monitoring until there is evidence of late

in patients randomized to deliver for late ductus venosus abnormal-

Doppler changes in the umbilical artery (AEDV or REDV), ductus

ity. Overall, cCTG was the most frequent trigger for delivery. In the

venosus alterations, or FHR abnormalities. Therefore, at the point

three arms, delivery was based on abnormal STV in 11%–51% of

when delivery is indicated in cases of severe early-onset FGR, the

participants, and visually apparent FHR decelerations led to delivery

fetus might already be experiencing some degree of hypoxia or aci-

in 22%–31% of participants. While the strategy of awaiting absent

dosis, 291 in which case the likelihood of the fetus tolerating labor is

or reversed ductus venosus a-wave to determine delivery produced

low and the rate of cesarean section has been reported to be greater

the better study outcome, it is noteworthy that the stillbirth rate

than 80%.351 In addition, labor induction in general is less likely to be

increased four-fold compared with patients who were monitored

successful during the preterm period.352,353 For these reasons, pri-

with cCTG and umbilical artery Doppler. In addition, an absent duc-

mary cesarean section is usually the preferred option when delivery

tus venosus a-wave only triggered delivery in 10% of participants in

is indicated in cases of severe early-onset FGR. 354

this study arm. The frequency of delivery decisions based on FHR

In contrast, late-onset FGR is usually less severe and fetal hypoxia

abnormalities emphasizes the importance of concurrently monitor-

or acidosis is less likely to be present at the time when delivery is

ing growth-restricted fetuses with more than one modality.

indicated. Indeed, in the DIGITAT trial the rate of vaginal delivery

Because cCTG is not universally available, most healthcare pro-

was greater than 80% in pregnancies induced for SGA with normal

viders need to rely on traditional CTG/NST monitoring. While BPP

umbilical artery Doppler after 36 weeks of gestation.347 This obser-

has not been studied in randomized intervention trials in FGR, it

vation suggests that most term SGA fetuses with normal umbilical

is an established monitoring tool to verify fetal status in patients

artery Doppler can tolerate labor and that the presence of late-onset

with a nonreactive tracing. In FGR, an abnormal BPP predicts ab-

FGR in the absence of additional factors does not preclude induc-

normal arterial pH with a similar accuracy to cCTG and is an inde-

tion of labor. Several studies have tried to individualize the decision

pendent delivery trigger at a comparable frequency to cCTG.304,319

regarding mode of delivery through the development of models for
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the prediction of urgent cesarean section in women with late-onset

attributed to peripheral vasodilatation or an increase in cardiac out-

SGA undergoing labor induction. The factors that were most pre-

put and circulatory stress.376,377 Despite this, recent data support

dictive of urgent cesarean section were gestational age, severity of

the efficacy and safety of antenatal corticosteroids in the subgroup

SGA (EFW <3rd percentile), cerebral Doppler (middle cerebral artery

of SGA fetuses,378,379 which should be administered when delivery

For example, in

is anticipated, ideally within 1–7 days before birth.380 When admin-

a large cohort study of 509 women undergoing labor induction for

istered in cases of severe FGR with late Doppler changes, an inpa-

late-onset SGA, the predictive model had a positive predictive value

tient setting is advised where the fetus can be closely monitored.

of 36% and a negative predictive value of 89% for urgent cesarean

Finally, it is important to recognize that the “improvement” in um-

section for nonreassuring fetal state.355 Thus, although this informa-

bilical artery Doppler that is often seen following administration of

tion can be helpful for patient counselling regarding mode of deliv-

antenatal corticosteroids is transient, and is thought to be the result

ery and may reassure women with none of these risk factors of the

of vasodilation of the fetoplacental arterial tree and increased fetal

high likelihood of a successful trial of labor (nearly 90%), the positive

cardiac output rather than a true decrease in placental resistance.381

predictive value of these models (i.e. a risk of cesarean section in the

Therefore, these transient changes should not be interpreted as an

range of 30%–40%) is not high enough to preclude a trial of labor

improvement in fetal status and should not affect the management

even when these risk factors are present.

plan. Of note, the absence of any change in end-diastolic flow in re-

and cerebroplacental ratio), and Bishop score.

355,356

The optimal approach for cervical ripening in women undergoing induction for FGR remains unclear. In a recent meta-analysis of

sponse to antenatal corticosteroids is a concern and predicts subsequent fetal deterioration.372

12 trials on cervical ripening in pregnancies complicated by SGA or
FGR, the authors concluded that mechanical methods (such as balloon catheters) seem to be associated with a lower risk of cesarean

8.4.2 | Magnesium sulfate for neuroprotection

section and intrapartum complications compared with alternatives
such as dinoprostone.357 Given these data, it seems reasonable to

Administration of magnesium sulfate to women at risk of preterm

prefer balloon catheter over prostaglandin preparations, when pos-

birth has been shown to have a neuroprotective role, with a decrease

sible, for cervical ripening in pregnancies with suspected FGR. If

in the risk of perinatal mortality, cerebral palsy, and gross motor

prostaglandin agents are used, a reversible method (e.g. dinopros-

dysfunction.382,383 Possible mechanisms thought to be involved

tone vaginal insert) should be preferred.

in the beneficial effects of magnesium sulfate include reducing

During labor, continuous FHR monitoring is recommended.

intracellular calcium levels, stabilizing blood pressure, normalizing

Delivery should take place at an institution with the appropriate

cerebral blood flow, blocking the effects of excitatory neurotrans-

level of neonatal care for the gestational age and the anticipated

mitters such as glutamate, and antioxidant and anti-inflammatory

management needs of the neonate.

effects.384,385 However, the optimal protocol for the administration

It is recommended that the placenta is sent for histopathological

of magnesium sulfate for the purpose of neuroprotection remains

evaluation after delivery. Ideally this should be done in accordance

unclear and available protocols vary with regard to the timing of

with the Amsterdam workshop consensus statement.

358

High-

quality evaluation of the placental pathology is not only likely to
increase the precision of the diagnosis but also provides information
on the risks of recurrence.18,359,360

administration, upper gestational age limit, dose, duration, and need
for repeat doses.386-389
The observation that term FGR infants have higher cord blood
magnesium levels compared with normally grown infants raises the
theoretical concern that maternal administration of magnesium sulfate in cases of FGR might result in toxic magnesium levels in the

8.4 | Medical interventions

fetus.390,391 However, there are currently no data on the efficacy and
safety of magnesium sulfate in FGR fetuses that can support or refute

8.4.1 | Antenatal corticosteroids

these theoretical concerns. Therefore, there is currently no evidence
in favor or against recommending administration of magnesium sul-

The efficacy of antenatal corticosteroids in cases of FGR has been

fate for neuroprotection in women at risk of preterm birth with sus-

questioned, based on reports of elevated endogenous cortisol levels

pected FGR.379 We believe that, at the current time, it is reasonable to

361-364

extrapolate the efficacy of magnesium sulfate to specific subgroups

In addition, the unique cardiovascular, hormonal, and metabolic

of pregnancies, including those complicated by FGR, especially given

changes characteristic of growth-restricted fetuses276,365-369 have

that FGR is an independent risk factor for cerebral palsy.

in this population when compared with normally grown fetuses.

raised concerns that exposure to exogenous steroids may produce
potentially harmful cardiovascular and metabolic effects in these
already compromised fetuses. Indeed, exposure to corticosteroids

8.4.3 | Treatments under investigation

has been shown to result in Doppler changes in growth-restricted
fetuses such as transient increase in diastolic flow in the umbilical

Several novel therapies aiming to improve poor placentation and

artery 370-373 and the middle cerebral artery,374-376 which have been

uterine blood flow are being explored, some of which are described
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below. However, there are currently no proven treatments for FGR,

delivery into the uterine arteries can be achieved with intervention

and any of the therapies currently under investigation should be

radiology. This approach is currently being investigated in the ongo-

evaluated only in an appropriately regulated research setting.392

ing EVERREST trial.398 Protein pump inhibitors have been shown in

Phosphodiesterase type-5 inhibitors, such as sildenafil citrate,

vitro to decrease sFlt-1 and soluble endoglin and improve markers

potentiate nitric oxide availability, lead to vasodilatation,393,394 and

of endothelial dysfunction. However, in a recent randomized trial

395

involving 120 women with preterm pre-eclampsia, esomeprazole did

However, in the recently published STRIDER trial, which randomized

not improve pregnancy outcomes.399 Pravastatin has been shown

135 women with early-onset FGR to 25 mg sildenafil three times

to have anti-inflammatory, antioxidant, and proangiogenic proper-

daily or placebo, sildenafil did not prolong pregnancy or improve

ties.400,401 However, in a recently published randomized trial of 94

pregnancy outcomes.396 More recently, a similar randomized trial

women with early-onset pre-eclampsia, the administration of 40 mg

was halted prematurely due to lack of benefit along with concerns

pravastatin daily did not lower maternal sFlt-1 levels or prolong preg-

that sildenafil may cause neonatal pulmonary hypertension.397

nancy when compared with placebo.402 Other novel potential thera-

can improve umbilical artery and middle cerebral artery Doppler.

Another approach is to target the uteroplacental circulation with

pies include nanoparticles and microRNAs that deliver drugs locally

maternal vascular endothelial growth factor gene therapy, thereby

to the uterine arterial endothelium or trophoblasts, to improve uter-

improving local vasodilatation and angiogenesis.392 Clinically, vector

ine blood flow and placental function.

8.5 | Recommendations
FIGO recommends the following for the management of fetal growth restriction (FGR)
Recommendation

Quality of
evidence

Strength of
recommendation

○○

Strong

○

Strong

⊕⊕

○○

Strong

4. Absolute indications for delivery irrespective of gestational age include biophysical profile or CTG/NST
abnormalities (reduced variability and/or repetitive late decelerations), or severe pre-eclampsia with
uncontrolled hypertension, HELLP syndrome, or other types of end organ damage.

⊕⊕⊕⊕

Strong

5. In cases of isolated mild SGA (estimated fetal weight at 3rd–9th percentile) with no additional
abnormalities (i.e. normal fluid and Doppler studies), delivery may be deferred until 37–39 weeks.
Until then, monitoring should include umbilical artery and middle cerebral artery Doppler at
an interval of 1–2 weeks. For mild SGA at term (≥37 weeks), monitoring with CTG/NST and/or
biophysical profile 1–2 times per week may be considered in addition to Doppler studies.

⊕⊕⊕

○

Strong

6. In cases of isolated severe SGA (estimated fetal weight <3rd percentile) with no additional
abnormalities, delivery may be deferred until 36–38 weeks. Until then, monitoring should include
umbilical artery and middle cerebral artery Doppler 1–2 times per week. For severe SGA at term
(≥37 weeks) monitoring with CTG/NST and/or biophysical profile 1–2 times per week may be
considered in addition to Doppler studies.

⊕⊕⊕

○

Strong

7. In cases of FGR with early Doppler changes or mild associated abnormalities (oligohydramnios,
suboptimal interval growth, pre-eclampsia), delivery may be deferred until 34–37 weeks. Until then,
monitoring should include CTG/NST and/or biophysical profile twice per week and Doppler 1–2 times
per week.

⊕⊕

○○

Strong

8. In cases of FGR with umbilical artery absent end-diastolic velocity (AEDV), delivery may be deferred
until 32 weeks. Until then, inpatient monitoring is recommended with CTG/NST and/or biophysical
profile 1–2 times per day and Doppler 3 times per week.

⊕⊕

○○

Strong

1. Fetal movement counting is a simple and inexpensive tool that may decrease the risk of stillbirth in
pregnancies with FGR in both high- and low-resource settings.

⊕⊕

2. Surveillance in pregnancies with FGR should follow a uniform protocol that is based on a combination
of biophysical (cardiotocogram/nonstress test [CTG/NST], computerized fetal heart rate monitoring
[cCTG], biophysical profile) and cardiovascular (umbilical artery and middle cerebral artery, with or
without ductus venosus Doppler) parameters along with predetermined thresholds for delivery.
LRS In low-resource settings, the combination of CTG/NST and umbilical artery Doppler provides
sufficient accuracy for the detection of fetal deterioration.

⊕⊕⊕

3. In late-onset FGR, middle cerebral artery Doppler and the cerebroplacental ratio can provide additional
information on fetal deterioration and should be included as part of the Doppler assessment.
LRS In cases where middle cerebral artery Doppler is not available, twice weekly CTG/NST
monitoring in cases of late FGR with normal umbilical artery Doppler provides a similar safety net as
middle cerebral artery Doppler.
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FIGO recommends the following for the management of fetal growth restriction (FGR) Cont.
Recommendation

Quality of
evidence

Strength of
recommendation

○○

Strong

○○

Weak

⊕⊕

○○

Strong

12. Delivery of FGR fetuses should ideally take place at centers with the appropriate level of neonatal
care for the gestational age and with the ability to perform urgent cesarean section if needed. During
labor, continuous fetal heart rate monitoring is recommended.

⊕⊕⊕⊕

Strong

13. The placenta should be sent for histopathological examination where available as it may provide
useful information for counselling regarding future pregnancies.

⊕⊕

○○

Strong

14. The administration of antenatal corticosteroids in FGR pregnancies should follow the same protocol
used in pregnancies not affected by FGR. Close fetal monitoring should be considered when antenatal
corticosteroids are administered in fetuses with severe FGR with late Doppler changes.

⊕⊕⊕

○

Strong

15. The administration of magnesium sulfate for neuroprotection in preterm FGR pregnancies should
follow the same protocol used in pregnancies not affected by FGR.

⊕⊕

○○

Strong

16. There are currently no proven treatments for FGR.

⊕⊕⊕

○

Strong

9. In cases of FGR with umbilical artery reversed end-diastolic velocity (REDV), delivery may be deferred
until 30 weeks. Until then, inpatient monitoring is recommended with CTG/NST and/or biophysical
profile twice per day and daily Doppler.

⊕⊕

10. In cases of FGR with abnormal ductus venosus Doppler, delivery may be recommended as early as
26–30 weeks. Timing should be individualized based on local neonatal outcomes. Intensive inpatient
monitoring is recommended with CTG/NST and/or biophysical profile twice per day and daily
Doppler. Before 26 weeks, careful and shared decision making with the parents and neonatology
team is recommended.

⊕⊕

11. FGR alone is not an indication for cesarean section. Primary cesarean section may be considered in
cases of early-onset FGR with late umbilical artery (AEDV/REDV) or ductus venosus Doppler changes,
abnormal CTG/NST or biophysical profile, maternal indications such as severe pre-eclampsia, or
contraindications for vaginal birth. In the absence of these conditions, induction of labor should be
preferred.
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heart disease or death (aHR 1.9; 95% CI, 1.5–2.4).417 Moreover, a
combination of FGR, pre-eclampsia, and preterm delivery amplified
the risk of disease seven-fold. For a detailed review of the evidence

9.1 | Infant follow-up

supporting these associations, their underlying mechanisms, and
recommendations on maternal follow-up and prevention strategies,

Growth-restricted infants are at increased risk of both immediate

please refer to the recently published FIGO postpregnancy initiative

and long-term complications, and therefore require closer follow-up

on long-term maternal implications of pregnancy complications and

than normally grown infants in the first years of life.

follow-up considerations.4

Growth-restricted infants have lower survival rates compared
with those appropriate for gestational age. 403 Although this may
be attributed in part to prematurity that is often associated with

9.3 | Counselling regarding future pregnancies

FGR, birth weight has been shown to be an independent prognostic factor for neonatal mortality, irrespective of gestational
age.

404

The most frequent and relevant question that care providers are

In a population-based cohort study, the mortality rate

being asked by couples whose prior pregnancy was complicated

of term FGR neonates was approximately five-fold higher com-

by FGR relates to the likelihood of a similar complication in subse-

pared with appropriate for gestational age neonates (0.3% vs

quent pregnancies. The answer to this question is often difficult and

0.06%). 405

depends on several factors, namely the underlying etiology, severity

FGR can affect postnatal growth. In cases of mild FGR, in-

and timing of onset, and the presence or absence of modifiable risk

fants tend to achieve normal height during the first year of

factors (e.g. maternal medical conditions or smoking). In cases of pla-

life.406 In cases affected by severe FGR, however, height in the

centa-mediated FGR, the results of the placental histopathological

late teens is lower than those born appropriate for gestational

examination may provide valuable information that can assist care

age (169.9 ± 1.5 vs 175.4 ± 0.8 cm; P < 0.0001 for boys; and

providers in counselling patients regarding the risk of recurrence,

159.4 ± 1.3 vs 163.1 ± 0.8 cm; P < 0.0005 for girls).407

role of further investigation, and potential preventive interventions

FGR infants are also at increased risk of adverse long-term neu-

in subsequent pregnancies.

rodevelopmental outcomes. A systematic review of this topic found
that FGR infants are at higher risk of poor neurodevelopmental outcomes measured up to 3 years of age; however, high levels of heterogeneity in primary outcomes were reported in the studies included

9.3.1 | Risk of recurrence based on
severity and onset

in the review.12 Of note, adverse neurodevelopmental outcomes
may at least partly be related to coexisting increased prematurity

Most of the data on the risk of recurrence of placenta-mediated

rates.408

complications come from studies evaluating hypertensive com-

In line with the developmental origins of health and disease

plications of pregnancy. In a recent individual patient data

hypothesis, FGR has been associated, in both animal and human

meta-analysis of 22 studies, the overall risk of recurrence of hyper-

studies, with an increased risk of future noncommunicable diseases

tensive complications was 21%, and was higher in women who ex-

including obesity, diabetes, hypertension, and cardiovascular dis-

perienced early-onset hypertensive complications.418 Data on the

ease.

409-411

The risk is especially high in those infants who experi-

ence rapid catch-up growth in the first few years of life.

412,413

recurrence of FGR are limited.419-422 In a population-based study,

The

the overall recurrence rate of FGR in women who gave birth to an

mechanisms underlying these associations are not entirely clear.

infant with a birth weight below the 10th percentile was 24%, com-

However, fetal programming by means of epigenetic changes as well

pared with 6% in women without a history of FGR (OR 3.9; 95% CI,

as direct organ damage are thought to play a role.414 Ongoing studies

3.7–4.0). The risk of recurrence was related to the severity of FGR,

are investigating the optimal follow-up and prevention strategies to

and was nearly six-fold when the infant birth weight was below

decrease the risk of these complications.

415,416

the 5th percentile (OR 5.7; 95% CI, 5.4–6.0).423 Thus, couples
with FGR in the first pregnancy can be reassured that the overall

9.2 | Maternal follow-up

chance of recurrence in subsequent pregnancies is less than 25%.
However, interpretation of the data is limited by the lack of distinction between constitutionally SGA infants and infants who were

It is well established that women with a history of pregnancy com-

truly growth restricted, as much of the association described in

plicated by FGR or other placenta-mediated complications such as

that study may be driven by the recurrence of constitutional SGA.

pre-eclampsia are at an increased risk of future cardiovascular dis-

Therefore, counselling regarding the risk of recurrence should be

ease, especially in the presence of early-onset disease. In a popula-

further refined based on the risk factors of the individual patient,

tion-based study that included more than 100 000 pregnancies and

severity of FGR as reflected by timing of onset and Doppler find-

provided maternal follow-up for 15–19 years, delivery of a low birth

ings, the co-presence of pre-eclampsia, and placental histopatho-

weight infant was associated with increased maternal risk of ischemic

logical findings.
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9.3.2 | Risk of recurrence based on placental
histopathology

41

The findings are clearer for inherited thrombophilias. Most prospective studies found no significant association between inherited
thrombophilia

and

placenta-mediated

complications.438-443

The results of the placental histopathological examination are

Furthermore, the TIPPS and FRUIT trials found no benefit of LMWH

important for two main reasons. First, they may assist care provid-

in women with thrombophilia and a history of placenta-mediated

ers in counselling couples regarding the most likely etiology of FGR,

pregnancy complications.444,445 These findings were confirmed by

especially when the clinical presentation and Doppler findings were

a recent individual patient data meta-analysis that found no benefit

inconclusive. Second, placental findings may provide valuable infor-

of LMWH in decreasing the risk of recurrence of placenta-mediated

mation regarding the risk of recurrence, as certain types of placental

complications, including in women with thrombophilia.140 Therefore,

pathologies are associated with a relatively high recurrence rate. The

there is no indication for routine screening for inherited thrombo-

main types of placental pathologies, the clinical phenotypes associ-

philia in women with prior FGR.446,447

ated with these pathologies, and their estimated risks of recurrence
are summarized in Table 2.424-426

9.3.3 | Role of thrombophilia screening

9.3.4 | Preconception counselling and
management of future pregnancies
Given the considerable risk of recurrence of FGR, efforts should be

Whether women who experienced placenta-mediated pregnancy

made to decrease this risk in future pregnancies.448 Modifiable risk

complications should be screened for antiphospholipid syndrome

factors for FGR such as smoking or poor nutritional status should be

is a matter of debate. Although the consensus criteria for antiphos-

identified as early as possible and managed accordingly, as discussed

pholipid syndrome include premature birth before 34 weeks for

in section 5.5.1.

severe pre-eclampsia or features consistent with placental insuf-

There is some evidence that administration of aspirin can reduce

ficiency including birth weight below the 10th percentile,427 the

the risk of FGR. However, as described in section 5.5.2 most available

association of antiphospholipid (aPL) antibodies with these condi-

data focused on the prevention of pre-eclampsia as the primary out-

tions is relatively weak and conflicting, especially for FGR.428-430 In

come in women at high risk of pre-eclampsia, with the prevention of

addition, although some care providers recommend treatment with

FGR being considered a secondary outcome. Data on the prevention

LMWH during pregnancy to women with aPL syndrome and previ-

of recurrence of FGR in women with a history of FGR are limited.449

ous preterm birth for placenta-mediated complications, this prac-

Therefore, some recommend that aspirin should be considered in

tice is mostly extrapolated from women with aPL syndrome and

women with past FGR only if they have risk factors for pre-eclampsia

recurrent pregnancy loss, where there is some evidence in favor

at the time of the next pregnancy.450 However, we believe that given

of LMWH.

431-433

However, the only trial on LMWH in women with

the safety of aspirin and the overlap in pathogenesis of pre-eclampsia

aPL syndrome and prior placenta-related complications (FRUIT

and FGR, it is reasonable to recommend aspirin to women with a his-

trial) found no evidence that LMWH improves outcomes in these

tory of placenta-mediated FGR in the previous pregnancy, using the

cases.

434

Given the above, there is insufficient evidence to justify

routine screening for aPL antibodies in women with prior FGR.435
However, screening for aPL antibodies is recommended in women

same regimen of aspirin used for the prevention of pre-eclampsia. This
recommendation is shared by most professional societies.134
Data on the role of LMWH to prevent recurrence of placenta-

with a history of thromboembolism or recurrent pregnancy loss

mediated complications including FGR are conflicting, and this topic

(or ≥1 late fetal loss), and may be considered in selected cases of

is reviewed in section 5.5.2. Based on available data, LMWH therapy

women with a history of severe FGR associated with severe early-

should not be used in women with a past history of FGR except in a

onset pre-eclampsia, when placental examination shows features

research setting.

of severe maternal vascular malperfusion, especially central or mul-

Given the association of insufficient gestational weight gain

tiple areas of villous infarction that are due to multiple spiral artery

with FGR, we recommend monitoring of weight gain and inform-

thromboses.

ing women about their target weight gain range, as described in

Management of women already diagnosed with antiphospho-

section 5.5.1. Other interventions, such as bed rest or nutritional

lipid syndrome based on a history of placenta-mediated complica-

supplements are of unproven benefit and should not be routinely

tions is also under debate. Based on the evidence from the FRUIT

offered.451,452 The risk of recurrence can be further stratified in

trial described above, some only recommend treatment with aspi-

early pregnancy by means of prenatal screening with biochemical

rin in this setting,436 while others recommend either surveillance or

markers (PAPP-A, beta hCG, alpha-fetoprotein, and PlGF) as well

LMWH during the antepartum and postpartum periods.437 Based on

as by uterine artery Doppler, as described in section 5. Due to the

available evidence we only recommend treatment with aspirin, and

increased risk of recurrence, pregnant women with a history of FGR

suggest that LMWH be considered only in selected cases, such as

in a previous pregnancy should be managed in a high-risk pregnancy

for women who have experienced recurrent complications despite

clinic and should receive closer antenatal surveillance, including

aspirin treatment (aspirin failure).

close monitoring of fetal growth and maternal blood pressure.453

Common

Relatively
common

Maternal vascular
malperfusion
(MVM)

Fetal vascular
malperfusion
(FVM)

Rare

Rare

Chronic
histiocytic
intervillositis

Massive perivillous
fibrinoid
deposition
(maternal floor
infarction)

Large amounts of
fibrinoid matrix
surrounding villi

Maternal histiocytic
infiltrate in the
intervillous space

Chronic T-cell
mediated
inflammation of
villous stroma

Avascular villi,
chorionic
plate or stem
villous thrombi,
obstructive lesions
of umbilical cord

Decidual arteriopathy,
agglutinated villi,
increased syncytial
knots, intervillous
fibrin deposition,
villous infarcts

Common placental
findings

Unclear

Maternal graft versus
host response to fetal
antigens in the placenta

Most common cause:
chronic/intermittent
cord obstruction due
to cord compression,
entanglement, or
hypercoiling.
Possible association with
hereditary thrombophilia

Placental malperfusion due
to shallow trophoblast
invasion and failure of
remodeling of spiral
arteries

Pathophysiology

Recurrent miscarriages,
recurrent severe earlyonset FGR, stillbirth

Recurrent miscarriages,
recurrent severe earlyonset FGR, stillbirth

Late-onset FGR, abnormal
neurodevelopmental
outcome, stillbirth

FGR, fetal CNS injury,
stillbirth

Early- or late-onset FGR,
pre-eclampsia, placental
abruption

Phenotype

40%–60%

70%–100%

10%–50%

Low

10%–25%

Risk of
recurrence

Consider screening for antiphospholipid
antibodies, hereditary
thrombophilia
Anecdotal reports of treatment with
aspirin, heparin, and IVIG

Suggested interventions include
prednisone, hydroxychloroquine,
aspirin, low-molecular-weight
heparin
Associated with increased levels
of serum alpha-fetoprotein and
alkaline phosphatase

Consider screening of the infant or the
mother for hereditary thrombophilia

Screening for antiphospholipid
antibodies may be considered in
selected cases of severe early-onset
FGR, when placental examination
shows features of severe MVM such
as especially central or multiple
areas of villous infarction
Consider aspirin in subsequent
pregnancy, especially if associated
with pre-eclampsia

Recommendations for investigation
and prevention in next pregnancy

426,463,470

469

461,463,465-

457-464

454-456

173,425

Refs

|

Abbreviations: CNS, central nervous system; FGR, fetal growth restriction; IVIG, intravenous immunoglobulins.

Relatively
common
(5%–10%
of term
placentas)

Villitis of
unknown
etiology (VUE)

Chronic inflammation

Incidence

Placental pathology

TA B L E 2 Phenotypes and risk of recurrence associated with specific types of placental pathologies.
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9.4 | Recommendations
FIGO recommends the following for postpartum assessment and counselling for future pregnancies in women with a history of fetal growth
restriction (FGR)
Recommendation

Quality of
evidence

○○

Strong

○

Strong

○○

Strong

⊕⊕⊕

○

Strong

○
⊕⊕○○

Strong

○

Strong

1. Growth-restricted infants are at an increased risk of short- and long-term morbidity and should be
followed postnatally more closely than normally grown infants.

⊕⊕

2. Women with a history of placenta-mediated pregnancy complications including FGR are at an increased
risk of future cardiovascular morbidity and should be advised regarding preventive strategies as
reviewed in detail in the FIGO postpregnancy initiative on long-term maternal implications of
pregnancy complications and follow-up considerations.4

⊕⊕⊕

3. Women with a history of FGR should be counselled regarding the risk of recurrence based on timing of
onset, severity of FGR, and placental histopathological findings.

⊕⊕

4. Women with a history of FGR should not be routinely screened for antiphospholipid antibodies in the
absence of a history of thromboembolism or pregnancy loss.
5. There is no role for screening for hereditary thrombophilias in women with a history of FGR.

⊕⊕⊕

6. The following preventive interventions are recommended in women with a history of placenta-mediated
FGR and those at risk of pre-eclampsia: smoking cessation, aspirin at a dose of 100–150 mg taken in
the evening starting at 12–16 weeks.

Strength of
recommendation

7. Low-molecular-weight heparin is not recommended for the prevention of FGR in women with a history
of placenta-mediated FGR.

⊕⊕⊕

8. In women with antiphospholipid syndrome and a history of placenta-mediated FGR, low-molecularweight heparin may be considered in selected cases, such as in women who have experienced
recurrent complications despite aspirin treatment (aspirin failure).

⊕⊕

9. Women with a history of FGR should undergo close surveillance of fetal growth starting at
24–28 weeks.

⊕⊕⊕

○○
○

Strong

Weak

Strong
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Future research should focus on the development of new fetal
assessment tools that may improve the accuracy of the prediction
of fetal deterioration and thus further optimize timing of delivery

FGR is an important cause of stillbirth, neonatal mortality, and short-

of FGR fetuses, as well as on novel treatments that may improve

and long-term neonatal morbidity. Early prediction and preventive

placental function in cases of placenta-mediated FGR and thereby

strategies, timely diagnosis, and management using a standardized

deferring delivery in cases of early-onset FGR.

protocol to determine the proper monitoring and timing of delivery
can decrease the risk of stillbirth and improve perinatal outcomes in
pregnancies complicated by FGR.

Melamed et al.
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